<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Orthop Surg Res</journal-id><journal-id journal-id-type="iso-abbrev">J Orthop Surg Res</journal-id><journal-title-group><journal-title>Journal of Orthopaedic Surgery and Research</journal-title></journal-title-group><issn pub-type="epub">1749-799X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40410779</article-id><article-id pub-id-type="pmc">PMC12102801</article-id>
<article-id pub-id-type="publisher-id">5883</article-id><article-id pub-id-type="doi">10.1186/s13018-025-05883-0</article-id><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>Restrictive versus Liberal blood transfusion strategies for patients undergoing orthopedic surgery: a meta-analysis of randomised trials with trial sequential analysis</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Zhou</surname><given-names>Zhou</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Xiao</surname><given-names>Zefeng</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Luo</surname><given-names>Yan</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Nie</surname><given-names>Tuanbiao</given-names></name><address><email>nietuanbiao@hnca.org.cn</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Xiao</surname><given-names>Xuelian</given-names></name><address><email>xiaoxuelian@hnca.org.cn</email></address><xref ref-type="aff" rid="Aff5">5</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Neurosurgery, The Affiliated Cancer Hospital of Xiangya School of Medicine, </institution><institution>Hunan Cancer Hospital, Central South University, </institution></institution-wrap>No. 283 Tongzipo Road, Yuelu District, Changsha, Hunan 410013 China </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Nursing, The Affiliated Cancer Hospital of Xiangya School of Medicine, </institution><institution>Hunan Cancer Hospital, Central South University, </institution></institution-wrap>No. 283 Tongzipo Road, Yuelu District, Changsha, Hunan 410013 China </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Orthopedics, Xiangya Hospital, </institution><institution>Central South University, </institution></institution-wrap>No. 87, Xiangya Road, Changsha, Hunan China </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Clinical Medicine Eight-Year Program, Xiangya Hospital, </institution><institution>Central South University, Central South University, </institution></institution-wrap>No. 87, Xiangya Road, Changsha, Hunan China </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00f1zfq44</institution-id><institution-id institution-id-type="GRID">grid.216417.7</institution-id><institution-id institution-id-type="ISNI">0000 0001 0379 7164</institution-id><institution>Department of Medical Administration, The Affiliated Cancer Hospital of Xiangya School of Medicine, </institution><institution>Hunan Cancer Hospital, Central South University, </institution></institution-wrap>No. 283 Tongzipo Road, Yuelu District, Changsha, Hunan 410013 China </aff></contrib-group><pub-date pub-type="epub"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>24</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><elocation-id>513</elocation-id><history><date date-type="received"><day>6</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>2</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article&#x02019;s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article&#x02019;s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">A meta-analysis was conducted to explore the prognostic differences of restrictive blood transfusion (RBT) versus liberal blood transfusion (LBT) strategies in orthopedic patients.</p></sec><sec><title>Methods</title><p id="Par2">A comprehensive search was performed in PubMed, Embase, Cochrane Central Register of Controlled Trials, Embase, and clinicaltrials.gov up to 20 October 2024. The quality of included studies was assessed according to Cochrane risk of bias, and quality of evidence was assessed using the GRADE system. We performed sensitivity and publication bias analyses and used trial sequential analysis (TSA) to assess the risk of random error in the analysis results.</p></sec><sec><title>Results</title><p id="Par3">19 studies involving 7833 patients were included in the analysis. Compared with LBT, RBT reduced transfusion rate and increased the occurrence of cardiovascular events (RR&#x02009;=&#x02009;1.44; 95% CI: 1.15&#x02013;1.80, <italic>P</italic>&#x02009;=&#x02009;0.001; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0%), mainly increased myocardial infarction (RR&#x02009;=&#x02009;1.70; 95% CI: 1.16&#x02013;2.48, <italic>P</italic>&#x02009;=&#x02009;0.006; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0%) rather than congestive heart failure. There were no significant differences between transfusion strategies in infection, thrombotic events, mortality, delirium and length of hospitalization. Results of subgroup analyses indicate that in patients at high risk for cardiovascular disease, RBT increases the risk of myocardial infarction and length of hospitalization. In addition, RBT are associated with lower overall infection rates and shorter length of hospitalization after joint replacement or revision surgery; and are associated with an increased risk of myocardial infarction after fracture repair surgery (RR&#x02009;=&#x02009;1.79; 95% CI: 1.21&#x02013;2.65, <italic>P</italic>&#x02009;=&#x02009;0.004). The TSA results show that transfusion rate and mortality (&#x02265;&#x02009;60 days) have reached the required information size. However, the evidence regarding the efficacy for the remaining outcomes analyzed remains inconclusive, likely due to insufficient numbers of patients in the existing studies.</p></sec><sec><title>Conclusions</title><p id="Par4">Compared with LBT, RBT increases the risk of cardiovascular events in orthopedic patients but does not affect adverse outcomes such as infection, thrombotic events, mortality, and delirium.</p></sec><sec><title>Trial registration</title><p id="Par5">No patients were involved in this study.</p></sec><sec><title>Graphical Abstract</title><p id="Par6">
<graphic position="anchor" xlink:href="13018_2025_5883_Figa_HTML" id="d33e283"/>
</p></sec><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1186/s13018-025-05883-0.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Blood transfusion</kwd><kwd>Orthopedic patients</kwd><kwd>Meta-analysis</kwd><kwd>Trial sequential analysis</kwd><kwd>Liberal transfusion</kwd><kwd>Restrictive transfusion</kwd></kwd-group><funding-group><award-group><funding-source><institution>Hunan Provincial Health Commission Foundation</institution></funding-source><award-id>D202315027975</award-id></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; BioMed Central Ltd., part of Springer Nature 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Background</title><p id="Par7">Red blood cell (RBC) transfusion is a common treatment used to rapidly enhance the oxygen-carrying capacity of the blood, with approximately 118&#x000a0;million units collected worldwide each year [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Delayed blood transfusion can lead to ischemic tissue injuries in patients, thereby increasing mortality. Conversely, transfusion may also elevate the incidence of various adverse events and associated hospitalization costs [<xref ref-type="bibr" rid="CR3">3</xref>]. Consequently, several published guidelines have discussed the appropriate threshold for RBC transfusion, generally recommending a restrictive threshold of 70&#x02013;80&#x000a0;g/L [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR8">8</xref>]. While RBT practices are primarily based on hemoglobin levels in most orthopedic surgeries, current blood transfusion strategies exhibit significant variability. The optimal approach to blood transfusion remains a subject of controversy, as there are no universally applicable standards, and transfusion-related adverse events still cannot be overlooked [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Multiple systematic reviews and meta-analyses have evaluated the effectiveness of blood transfusion (RBT) (initiated mainly when hemoglobin level reach 8.0&#x000a0;g/dL or in cases of symptomatic anemia) versus liberal blood transfusion (LBT) (initiated mainly when hemoglobin level reach 10.0&#x000a0;g/dL) in orthopedic surgery patients [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>]. However, results have been inconsistent and inconclusive across different patient features and clinical surgery types [<xref ref-type="bibr" rid="CR11">11</xref>&#x02013;<xref ref-type="bibr" rid="CR16">16</xref>].</p><p id="Par8">In recent years, several pertinent randomized controlled trials (RCTs) have been published [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>], including a study by Quaranta et al. [<xref ref-type="bibr" rid="CR20">20</xref>] showing that orthogeriatric multidisciplinary care in elderly hip fracture patients improved postoperative hemoglobin and reduced transfusions, especially after hemiarthroplasty and highlighting the need for comprehensive reviews and meta-analyses to elucidate the clinical outcomes associated with different transfusion strategies. This study aims to thoroughly evaluate the safety and prognostic differences between RBT and LBT practices in orthopedic patients. We conducted meta-analyses and subgroup analyses to identify patient characteristics and surgical approaches that may influence these prognostic differences. Notably, we employed trial sequential analysis (TSA) to assess both the adequacy and reliability of the accumulated published evidence, as well as to evaluate the heterogeneity of study results and the potential for publication bias.</p></sec><sec id="Sec2"><title>Methods</title><sec id="Sec3"><title>Registration and protocol</title><p id="Par9">This meta-analysis was based on the Cochrane Handbook, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [<xref ref-type="bibr" rid="CR21">21</xref>] and assessment of multiple systematic reviews (AMSTAR) guidelines [<xref ref-type="bibr" rid="CR22">22</xref>]. The protocol of this study has been prospectively registered and published in the PROSPERO, and there has been no deviation from the protocol.</p></sec><sec id="Sec4"><title>Search strategy</title><p id="Par10">PubMed, Web of Science, EMBASE, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov (<ext-link ext-link-type="uri" xlink:href="http://www.controlledtrials.com/">http://www.controlledtrials.com/</ext-link>) were searched up to 20 October 2024. We constructed search terms using appropriate combinations of the following combined search terms with MeSH terms and adjusted accordingly for different databases: (blood transfusion) AND (orthopedic surgery) AND (randomized controlled trials). Details of the search strategy are provided in the Supplementary materials.</p></sec><sec id="Sec5"><title>Criteria for inclusion and exclusion</title><p id="Par11">Inclusion criteria: [<xref ref-type="bibr" rid="CR1">1</xref>] Randomized controlled trials; [<xref ref-type="bibr" rid="CR2">2</xref>] Study participants were patients undergoing orthopedic surgery; [<xref ref-type="bibr" rid="CR3">3</xref>] Study groups included at least a RBT group and a LBT group; [<xref ref-type="bibr" rid="CR4">4</xref>] Studies reported at least one primary or secondary outcome of this meta-analysis.</p><p id="Par12">Exclusion criteria: [<xref ref-type="bibr" rid="CR1">1</xref>] Conference abstracts, cohort studies, meta-analyses, editorials, and reviews; [<xref ref-type="bibr" rid="CR2">2</xref>] Duplicate publications; [<xref ref-type="bibr" rid="CR3">3</xref>] No detailed extractable data reported; [<xref ref-type="bibr" rid="CR5">5</xref>] Animal experiments.</p></sec><sec id="Sec6"><title>Literature screen and data collection</title><p id="Par13">After searching the literature, two authors independently screened the literature, first excluded duplicate literature, then read the abstracts to exclude irrelevant studies and finally reviewed the full text to determine the final included articles. Two authors then independently extracted data, including article characteristics and outcome data, from studies that met the inclusion criteria. When disagreements occurred, a third author joined the discussion to reach consensus.</p></sec><sec id="Sec7"><title>Outcomes</title><p id="Par14">Our primary outcomes were overall infection rates and cardiovascular event rates. For the overall infection, we considered all infections reported in the study. Cardiovascular events include myocardial infarction (MI), congestive heart failure (CHF) and arrhythmia (For relevant definitions, refer to the Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. Secondary outcomes included lung infection, wound infection, MI, CHF, thromboembolic events, cerebrovascular accidents, overall mortality, transfusion rates, delirium and length of hospitalization. In the subgroup analysis, the definitions of patients at high risk for cardiovascular disease and ordinary patients are shown in the Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>.</p></sec><sec id="Sec8"><title>Quality assessment and data synthesis and analysis</title><p id="Par15">The risk of bias of included studies was assessed according to the Cochrane Collaboration tool. Following the GRADE manual, GRADEpro 3.6 was used to assess the quality of evidence for meta-analyses. Two authors independently assessed the risk of bias and quality of evidence, and in case of inconsistencies, a third author participated in a discussion to obtain the final results. Dichotomous variables and continuous variables were expressed as risk ratio (RR) and standard mean difference (SMD), respectively, with a confidence interval (CI) of 95%. <italic>I</italic><sup><italic>2</italic></sup> is a quantitative measure used to assess the degree of heterogeneity. <italic>I</italic><sup><italic>2</italic></sup>&#x02009;&#x0003c;&#x02009;50% is considered to have insignificant heterogeneity, while <italic>I</italic><sup><italic>2</italic></sup>&#x02009;&#x0003e;&#x02009;50% indicates that heterogeneity may be significant. <italic>I</italic><sup><italic>2</italic></sup>&#x02009;&#x0003e;&#x02009;75% indicates high heterogeneity. When <italic>I</italic><sup><italic>2</italic></sup>&#x02009;&#x0003c;&#x02009;50%, the fixed effects model is used for analysis; otherwise, the random effects model is used. Sensitivity analysis is used to evaluate the impact of each study on the final total effect. Publication bias was assessed using Egger&#x02019;s test, and <italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05 was considered statistically significant. If p was &#x02265;&#x02009;0.5 and there was sufficient data, the trim-and-fill method was used to adjust for this bias [<xref ref-type="bibr" rid="CR23">23</xref>]. RevMan 5.4 software and Stata 14.0 software were used for analysis.</p></sec><sec id="Sec9"><title>Trial sequential analysis</title><p id="Par16">We performed TSA to assess whether the currently accumulated clinical data are sufficient to determine the conclusiveness of the results while assessing the risk of random error [<xref ref-type="bibr" rid="CR24">24</xref>]. The relative risk reduction was predefined as 20%, the &#x003b1; value was set at 5%, the &#x003b2; value was set at 20% (80% power), and the control event rate was calculated based on the restricted RBC transfusion group. Based on the above information, we calculated the required information size (RIS) for each result using TSA Viewer 0.9 beta software.</p></sec></sec><sec id="Sec10"><title>Results</title><sec id="Sec11"><title>Literature retrieval and screening</title><p id="Par17">The literature screening flow chart is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>. After the database search, 10,121 potentially relevant publications were detected. Among them, 4665 duplicate documents were deleted. 5405 articles were excluded because they did not meet the title and abstract review. 32 articles were excluded due to ineligibility after reading the full text (see the supplementary materials for reasons of exclusion), and 19 studies were finally included in this meta-analysis [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>]. We also noticed that the search results of PubMed showed that the number of publications related to blood transfusion and orthopedic surgery has increased rapidly in recent years (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>A), indicating that it is currently a hot topic.</p><p id="Par18">
<fig id="Fig1"><label>Fig. 1</label><caption><p>Literature screening flow chart</p></caption><graphic xlink:href="13018_2025_5883_Fig1_HTML" id="d33e502"/></fig>
</p><p id="Par19">
<fig id="Fig2"><label>Fig. 2</label><caption><p>An overview of studies characteristics, including distribution of (<bold>A</bold>) PubMed timeline results by year (<bold>B</bold>) publications by year (<bold>C</bold>) region (<bold>D</bold>) types of orthopedic surgery (<bold>E</bold>) and patient characteristics</p></caption><graphic xlink:href="13018_2025_5883_Fig2_HTML" id="d33e528"/></fig>
</p></sec><sec id="Sec12"><title>Study characteristics</title><p id="Par20">Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref> summarizes the characteristics of the included studies, and Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref> summarizes the included participant characteristics and transfusion information. These 19 studies were conducted from 1998 to 2024 (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>B) and were carried out in the United States, Canada, Denmark, the United Kingdom, India and other places (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>C). The total number of patients was 7833, of which 3918 were in the RBT group and the rest were in the LBT group. Fourteen studies were fracture repair surgeries [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>], four studies were joint replacement surgeries [<xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR33">33</xref>], and one study was joint revision surgeries [<xref ref-type="bibr" rid="CR34">34</xref>](Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>D). Five studies included patients at high risk for cardiovascular disease [<xref ref-type="bibr" rid="CR30">30</xref>&#x02013;<xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], and the remainder were from the general population (Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>E). In the included studies, hemoglobin thresholds ranged from 5.5&#x000a0;g/dl to 9.7&#x000a0;g/dl in the RBT group and from 7.0&#x000a0;g/dl to 10.0&#x000a0;g/dl in the LBT group. Of note, two study explored the relative safety of more conservative RBT (threshold 5.5&#x000a0;g/dL) versus more liberal LBT (threshold 7.0&#x000a0;g/dL) in asymptomatic orthopedic patients during the initial resuscitation period, which are extreme thresholds [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Five studies used leukocyte-reduced blood components [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. The included trials all used perioperative blood transfusion, including before, during and after surgery.</p><p id="Par21">
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of included studies</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Study</th><th align="left" rowspan="2">Region</th><th align="left" rowspan="2">Participants (<italic>n</italic>)</th><th align="left" rowspan="2">Type of surgery</th><th align="left" colspan="2">Restrictive blood transfusion strategies</th><th align="left" colspan="2">Liberal blood transfusion strategies</th><th align="left" rowspan="2">Follow-up</th></tr><tr><th align="left">Number of people</th><th align="left">Transfusion threshold</th><th align="left">Number of people</th><th align="left">Transfusion threshold</th></tr></thead><tbody><tr><td align="left">Carson 1998</td><td align="left">US and Scotland</td><td char="." align="char">84</td><td align="left">Hip fracture repair</td><td char="." align="char">42</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;8.0&#x000a0;g/dl or symptomatic anemia</td><td char="." align="char">42</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;10.0&#x000a0;g/dl</td><td align="left">Postoperative 60 days</td></tr><tr><td align="left">Lotke 1999</td><td align="left">US</td><td char="." align="char">152</td><td align="left">Total knee replacement</td><td char="." align="char">62</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;9.0&#x000a0;g/dL</td><td char="." align="char">65</td><td align="left">Beginning immediately after surgery</td><td align="left">Postoperative 4 days</td></tr><tr><td align="left">Grover 2006</td><td align="left">Southeast England</td><td char="." align="char">260</td><td align="left">Total hip or knee replacement</td><td char="." align="char">130</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;8.0&#x000a0;g/dl, maintenance range, 8.0&#x02013;9.5&#x000a0;g/dl</td><td char="." align="char">130</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;10.0&#x000a0;g/dl, mainte_x005f_x005f_x005f_x0002_nance range, 10.0&#x02013;12.0&#x000a0;g/dl</td><td align="left">Postoperative 5 days</td></tr><tr><td align="left">Foss 2009</td><td align="left">Denmark</td><td char="." align="char">120</td><td align="left">Hip fracture repair</td><td char="." align="char">60</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;8.0&#x000a0;g/dl</td><td char="." align="char">60</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;10.0&#x000a0;g/dl</td><td align="left">Postoperative 3 days</td></tr><tr><td align="left">So-Osman 2010</td><td align="left">Dutch</td><td char="." align="char">619</td><td align="left">Total hip or knee replacement</td><td char="." align="char">309</td><td align="left">Threshold range,6.4&#x02013;9.7&#x000a0;g/dl</td><td char="." align="char">310</td><td align="left">Varied by hospital, age and condition of patients, symptoms and time</td><td align="left">14 days after surgery or at final discharge</td></tr><tr><td align="left">Carson 2011</td><td align="left">US and Canada</td><td char="." align="char">2016</td><td align="left">Hip fracture repair</td><td char="." align="char">1009</td><td align="left">Symptomatic anemia or if Hb&#x02009;&#x0003c;&#x02009;8.0&#x000a0;g/dL</td><td char="." align="char">1007</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;10.0&#x000a0;g/dl</td><td align="left">Postoperative 60 days</td></tr><tr><td align="left">Carson 2015</td><td align="left">US and Canada</td><td char="." align="char">2016</td><td align="left">Hip fracture repair</td><td char="." align="char">1009</td><td align="left">Symptomatic anemia or if Hb&#x02009;&#x0003c;&#x02009;8.0&#x000a0;g/dL</td><td char="." align="char">1007</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;10.0&#x000a0;g/dl</td><td align="left">Median follow-up of 3 years</td></tr><tr><td align="left">Zhang 2024</td><td align="left">US and Canada</td><td char="." align="char">805</td><td align="left">Hip fracture repair</td><td char="." align="char">403</td><td align="left">Symptomatic anemia or if Hb&#x02009;&#x0003c;&#x02009;8.0&#x000a0;g/dL</td><td char="." align="char">402</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;10.0&#x000a0;g/dl</td><td align="left">Postoperative 30 and 60 days</td></tr><tr><td align="left">Gruber-Baldini 2013</td><td align="left">US and Canada</td><td char="." align="char">139</td><td align="left">Hip fracture repair</td><td char="." align="char">72</td><td align="left">Symptoms or &#x02264;&#x02009;8&#x000a0;g/dL</td><td char="." align="char">66</td><td align="left">&#x02264;&#x02009;10&#x000a0;g/dL</td><td align="left">Postrandomization days 5</td></tr><tr><td align="left">Parker 2013</td><td align="left">Canada</td><td char="." align="char">200</td><td align="left">Hip fracture repair</td><td char="." align="char">100</td><td align="left">8.0&#x02013;9.5&#x000a0;g/dl and symptomatic anemia</td><td char="." align="char">100</td><td align="left">8.0&#x02013;9.5&#x000a0;g/dl</td><td align="left">Postoperative 1 year</td></tr><tr><td align="left">Fan 2014</td><td align="left">China</td><td char="." align="char">192</td><td align="left">Total hip replacement</td><td char="." align="char">96</td><td align="left">Symptomatic anemia or Hb&#x02009;&#x0003c;&#x02009;8.0&#x000a0;g/dl,</td><td char="." align="char">96</td><td align="left">maintenance&#x02009;&#x02265;&#x02009;10&#x000a0;g/dl</td><td align="left">Postoperative 7 days</td></tr><tr><td align="left">Nielsen 2014</td><td align="left">Denmark</td><td char="." align="char">66</td><td align="left">Hip revision</td><td char="." align="char">33</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;7.3&#x000a0;g/dL</td><td char="." align="char">33</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;8.9&#x000a0;g/dL</td><td align="left">Postoperative 30 days</td></tr><tr><td align="left">Gregersen 2015a</td><td align="left">Denmark</td><td char="." align="char">284</td><td align="left">Hip fracture repair</td><td char="." align="char">144</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;9.7&#x000a0;g/dl</td><td char="." align="char">140</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;11.3&#x000a0;g/dl</td><td align="left">Postoperative 90 days</td></tr><tr><td align="left">Gregersen 2015b</td><td align="left">Denmark</td><td char="." align="char">284</td><td align="left">Hip fracture repair</td><td char="." align="char">144</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;9.7&#x000a0;g/dl</td><td char="." align="char">140</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;11.3&#x000a0;g/dl</td><td align="left">Postoperative 10 and 30 days</td></tr><tr><td align="left">Gregersen 2015c</td><td align="left">Denmark</td><td char="." align="char">157</td><td align="left">Hip fracture repair</td><td char="." align="char">80</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;9.7&#x000a0;g/dl</td><td char="." align="char">77</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;11.3&#x000a0;g/dl</td><td align="left">Postoperative 30 days and 1 year</td></tr><tr><td align="left">Blandfort 2017</td><td align="left">Denmark</td><td char="." align="char">179</td><td align="left">Hip fracture repair</td><td char="." align="char">89</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;9.7&#x000a0;g/dl</td><td char="." align="char">90</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;11.3&#x000a0;g/dl</td><td align="left">Postoperative 10 days</td></tr><tr><td align="left">Gillies 2021</td><td align="left">UK</td><td char="." align="char">62</td><td align="left">Neck of femur fracture repair</td><td char="." align="char">36</td><td align="left">Hb&#x02009;&#x02264;&#x02009;7.0&#x000a0;g/dl</td><td char="." align="char">26</td><td align="left">7.0&#x02013;9.0&#x000a0;g/dl</td><td align="left">Postoperative 30 and 60 days</td></tr><tr><td align="left">Mullis 2024a</td><td align="left">India</td><td char="." align="char">99</td><td align="left">Fracture repair</td><td char="." align="char">50</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;5.5&#x000a0;g/dL</td><td char="." align="char">49</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;7.0&#x000a0;g/dL</td><td align="left">2 weeks and 30 days after injury</td></tr><tr><td align="left">Mullis 2024b</td><td align="left">India</td><td char="." align="char">99</td><td align="left">Fracture repair</td><td char="." align="char">50</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;5.5&#x000a0;g/dL</td><td char="." align="char">49</td><td align="left">Hb&#x02009;&#x0003c;&#x02009;7.0&#x000a0;g/dL</td><td align="left">6 months and 1 year</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: Hb: hemoglobin</p></table-wrap-foot></table-wrap>
</p><p id="Par22">
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Characteristics and transfusion information of patients included in the study</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Study</th><th align="left" colspan="2">Age</th><th align="left" colspan="2">Number of males and females (M: F)</th><th align="left" rowspan="2">Patient characteristics</th><th align="left" rowspan="2">RBCs (type/suspension/leucocyte reduced)</th><th align="left" colspan="2">Baseline Hemoglobin</th><th align="left" colspan="2">RBC Transfused</th><th align="left" colspan="2">Transfusion rate</th></tr><tr><th align="left">
<italic>R</italic>
</th><th align="left">F</th><th align="left">
<italic>R</italic>
</th><th align="left">F</th><th align="left">
<italic>R</italic>
</th><th align="left">F</th><th align="left">
<italic>R</italic>
</th><th align="left">F</th><th align="left">
<italic>R</italic>
</th><th align="left">F</th></tr></thead><tbody><tr><td align="left">Carson 1998</td><td align="left">83.3&#x02009;&#x000b1;&#x02009;10.8</td><td align="left">81.3&#x02009;&#x000b1;&#x02009;8.1</td><td align="left">9:33</td><td align="left">11:31</td><td align="left">Patients with primary hip fracture</td><td align="left">Allogen/NA/NA</td><td align="left">(9.1&#x02009;&#x000b1;&#x02009;0.6) g/dl</td><td align="left">(9.1&#x02009;&#x000b1;&#x02009;0.6) g/dl</td><td align="left">0 (Median) (IQR 0&#x02013;2) units</td><td align="left">2 (median) (IQR 1&#x02013;2)</td><td align="left">19 (45.2%)</td><td align="left">41 (97.6%)</td></tr><tr><td align="left">Lotke 1999</td><td align="left">68.7</td><td align="left">69.7</td><td align="left">20:42</td><td align="left">20:45</td><td align="left">Total knee arthroplasty, osteoarthritis in 88% patients</td><td align="left">Allogen/NA/NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Grover 2006</td><td align="left">70.7&#x02009;&#x000b1;&#x02009;7.1</td><td align="left">71.5&#x02009;&#x000b1;&#x02009;7.6</td><td align="left">48:61</td><td align="left">55:45</td><td align="left">Elective total knee or hip arthroplasty</td><td align="left">Allogen/NA/leucocyte reduced</td><td align="left">(13.1&#x02009;&#x000b1;&#x02009;1.22) g/dl</td><td align="left">(13.6&#x02009;&#x000b1;&#x02009;1.22) g/dl</td><td align="left">0 (Median) (Range 0&#x02013;5) units</td><td align="left">0 (Median) (Range 0&#x02013;10) units</td><td align="left">37 (34%)</td><td align="left">46 (43%)</td></tr><tr><td align="left">Foss 2009</td><td align="left">81&#x02009;&#x000b1;&#x02009;7.3</td><td align="left">81&#x02009;&#x000b1;&#x02009;6.8</td><td align="left">14:46</td><td align="left">14:46</td><td align="left">Patients with primary hip fracture</td><td align="left">Allogen/NA/leucocyte reduced</td><td align="left">No available but graphed</td><td align="left">No available but graphed</td><td align="left">1 (Median) (IQR 1&#x02013;2) units</td><td align="left">2 (Median) (IQR 1&#x02013;2) units</td><td align="left">22 (37%</td><td align="left">44 (74%)</td></tr><tr><td align="left">So-Osman 2010</td><td align="left">70.7&#x02009;&#x000b1;&#x02009;10.2</td><td align="left">70.3&#x02009;&#x000b1;&#x02009;9.7</td><td align="left">84:215</td><td align="left">118:186</td><td align="left">Elective orthopaedic surgery patients</td><td align="left">Allogen/NA/leucocyte reduced</td><td align="left">(13.7&#x02009;&#x000b1;&#x02009;1.4) g/dl</td><td align="left">(13.7&#x02009;&#x000b1;&#x02009;1.4) g/dl</td><td align="left">0.78 (Mean)&#x02009;&#x000b1;&#x02009;1.4 (SD)</td><td align="left">0.86 (Mean)&#x02009;&#x000b1;&#x02009;1.6 (SD)</td><td align="left">105 (35%)</td><td align="left">93 (31%)</td></tr><tr><td align="left">Carson 2011</td><td align="left">81.5&#x02009;&#x000b1;&#x02009;9.0</td><td align="left">81.8&#x02009;&#x000b1;&#x02009;8.8</td><td align="left">239:770</td><td align="left">250:757</td><td align="left">Hip fracture patients at high risk for cardiovascular disease</td><td align="left">NA/NA/leucocyte reduced</td><td align="left">(11.3&#x02009;&#x000b1;&#x02009;1.5) g/dl</td><td align="left">(11.3&#x02009;&#x000b1;&#x02009;1.5) g/dl</td><td align="left">0 (Median) (IQR 0&#x02013;1) units</td><td align="left">2 (Median) (IQR 1&#x02013;2) units</td><td align="left">413 (41%)</td><td align="left">970 (97%)</td></tr><tr><td align="left">Carson 2015</td><td align="left">81.5&#x02009;&#x000b1;&#x02009;9.0</td><td align="left">81.8&#x02009;&#x000b1;&#x02009;8.8</td><td align="left">239:770</td><td align="left">250:757</td><td align="left">Hip fracture patients at high risk for cardiovascular disease</td><td align="left">NA/NA/leucocyte reduced</td><td align="left">(11.3&#x02009;&#x000b1;&#x02009;1.5) g/dl</td><td align="left">(11.3&#x02009;&#x000b1;&#x02009;1.5) g/dl</td><td align="left">0 (Median) (IQR 0&#x02013;1) units</td><td align="left">2 (Median) (IQR 1&#x02013;2) units</td><td align="left">413 (41%)</td><td align="left">970 (97%)</td></tr><tr><td align="left">Zhang 2024</td><td align="left">82.2&#x02009;&#x000b1;&#x02009;8.2</td><td align="left">82.4&#x02009;&#x000b1;&#x02009;8.5</td><td align="left">120:283</td><td align="left">137:265</td><td align="left">Patients with coronary artery disease</td><td align="left">NA/NA/NA</td><td align="left">(11.2&#x02009;&#x000b1;&#x02009;1.5) g/dl</td><td align="left">(11.3&#x02009;&#x000b1;&#x02009;1.4) g/dl</td><td align="left">0 (Median) (IQR 0&#x02013;1) units</td><td align="left">2 (Median) (IQR 1&#x02013;2) units</td><td align="left">128 (31.8%)</td><td align="left">110 (27.4%)</td></tr><tr><td align="left">Gruber-Baldini 2013</td><td align="left">80.6&#x02009;&#x000b1;&#x02009;10.4</td><td align="left">82.4&#x02009;&#x000b1;&#x02009;7.4</td><td align="left">25:47</td><td align="left">12:54</td><td align="left">Cardiovascular patients undergoing surgical hip fracture repair</td><td align="left">NA/NA/NA</td><td align="left">(11.9&#x02009;&#x000b1;&#x02009;1.7) g/dl</td><td align="left">(11.9&#x02009;&#x000b1;&#x02009;1.3) g/dl</td><td align="left">0 (Median) units</td><td align="left">2 (Median) units</td><td align="left">33(45.8%)</td><td align="left">63 (95.4%</td></tr><tr><td align="left">Parker 2013</td><td align="left">84.2</td><td align="left">84.4</td><td align="left">15:85</td><td align="left">17:83</td><td align="left">Patients with primary hip fracture</td><td align="left">NA/NA/NA</td><td align="left">11.8&#x000a0;g/dl</td><td align="left">11.5&#x000a0;g/dl</td><td align="left">No one received a blood transfusion</td><td align="left">All patients received a blood transfusion with a mean of 1.9 units</td><td align="left">0 (0%)</td><td align="left">100 (100%)</td></tr><tr><td align="left">Fan 2014</td><td align="left">75&#x02009;&#x000b1;&#x02009;6</td><td align="left">73&#x02009;&#x000b1;&#x02009;7</td><td align="left">30:64</td><td align="left">33:59</td><td align="left">Patients undergoing elective unilateral total hip replacement</td><td align="left">NA/NA/NA</td><td align="left">(12.0&#x02009;&#x000b1;&#x02009;1.1) g/dl</td><td align="left">(11.8&#x02009;&#x000b1;&#x02009;1.2) g/dl</td><td align="left">NA</td><td align="left">NA</td><td align="left">41(43.6%)</td><td align="left">52 (56.5%)</td></tr><tr><td align="left">Nielsen 2014</td><td align="left">68</td><td align="left">72</td><td align="left">16:17</td><td align="left">20:23</td><td align="left">Patients undergoing elective hip revision surgery</td><td align="left">NA/NA/NA</td><td align="left">13.4 (10.2&#x02013;15.0) g/dL</td><td align="left">13.8 (10.5&#x02013;16.3) g/dL</td><td align="left">median with (5&#x02013;95% range): 0 (0&#x02013;245)</td><td align="left">median with (5&#x02013;95% range): 0 (0&#x02013;245)</td><td align="left">11 (33.3%)</td><td align="left">16 (48.4%)</td></tr><tr><td align="left">Gregersen 2015a</td><td align="left">85.7&#x02009;&#x000b1;&#x02009;6.9</td><td align="left">86.9&#x02009;&#x000b1;&#x02009;9.8</td><td align="left">36:108</td><td align="left">34:106</td><td align="left">Patients with hip fracture</td><td align="left">NA/NA/NA</td><td align="left">(10.4&#x02009;&#x000b1;&#x02009;1.31) g/dl</td><td align="left">(10.3&#x02009;&#x000b1;&#x02009;1.44) g/dl</td><td align="left">1 (IQR 1&#x02013;2) units</td><td align="left">3 (IQR 2&#x02013;5) units</td><td align="left">24 (16%)</td><td align="left">20 (14%)</td></tr><tr><td align="left">Gregersen 2015b</td><td align="left">85.7&#x02009;&#x000b1;&#x02009;6.9</td><td align="left">86.9&#x02009;&#x000b1;&#x02009;9.8</td><td align="left">36:108</td><td align="left">34:106</td><td align="left">Patients with hip fracture</td><td align="left">NA/NA/NA</td><td align="left">(10.4&#x02009;&#x000b1;&#x02009;1.31) g/dl</td><td align="left">(10.3&#x02009;&#x000b1;&#x02009;1.44) g/dl</td><td align="left">1 (IQR 1&#x02013;2) units</td><td align="left">3 (IQR 2&#x02013;5) units</td><td align="left">24 (16%)</td><td align="left">20 (14%)</td></tr><tr><td align="left">Gregersen 2015c</td><td align="left">85.5&#x02009;&#x000b1;&#x02009;6.5</td><td align="left">87.2&#x02009;&#x000b1;&#x02009;7.3</td><td align="left">18:62</td><td align="left">17:60</td><td align="left">Patients with hip fracture</td><td align="left">NA/NA/NA</td><td align="left">(11.3&#x02009;&#x000b1;&#x02009;0.1) g/dl</td><td align="left">(12.3&#x02009;&#x000b1;&#x02009;0.2) g/dl</td><td align="left">1.5 (IQR 1&#x02013;2.5) units</td><td align="left">3 (IQR 2&#x02013;4) units</td><td align="left">61 (76%)</td><td align="left">77 (100%)</td></tr><tr><td align="left">Blandfort 2017</td><td align="left">86.5&#x02009;&#x000b1;&#x02009;6.7</td><td align="left">88.7&#x02009;&#x000b1;&#x02009;6.3</td><td align="left">22:67</td><td align="left">22:68</td><td align="left">Patients with hip fracture</td><td align="left">NA/NA/NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td></tr><tr><td align="left">Gillies 2021</td><td align="left">82&#x02009;&#x000b1;&#x02009;11</td><td align="left">82&#x02009;&#x000b1;&#x02009;11</td><td align="left">10:26</td><td align="left">8:16</td><td align="left">Patients with fractured neck of femur</td><td align="left">NA/NA/NA</td><td align="left">(12.0&#x02009;&#x000b1;&#x02009;1.5) g/dl</td><td align="left">(11.5&#x02009;&#x000b1;&#x02009;1.5) g/dl</td><td align="left">NA</td><td align="left">NA</td><td align="left">24 (67%)</td><td align="left">24 (92%)</td></tr><tr><td align="left">Mullis 2024a</td><td align="left">35.5</td><td align="left">30</td><td align="left">31:19</td><td align="left">33:16</td><td align="left">Patients with musculoskeletal trauma</td><td align="left">NA/NA/NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">50 (100%)</td><td align="left">46 (93.8%)</td></tr><tr><td align="left">Mullis 2024b</td><td align="left">35.5</td><td align="left">30</td><td align="left">31:19</td><td align="left">33:16</td><td align="left">Patients with musculoskeletal trauma</td><td align="left">NA/NA/NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">NA</td><td align="left">50 (100%)</td><td align="left">46 (93.8%)</td></tr></tbody></table><table-wrap-foot><p>R: restrictive blood transfution strategies; L: liberal blood transfution strategies; RBC: red blood cell; NA: not available; SD: standard deviation; IQR: inter-quartile range</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec13"><title>Risk of bias in the eligible studies and quality of evidence</title><p id="Par23">The risk of bias of the included studies is shown in Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>. 17 articles provide explicit methods for randomized sequence generation [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. 16 studies provided actual allocation concealment procedures [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR39">39</xref>]. One article reported the actual blinding procedure [<xref ref-type="bibr" rid="CR39">39</xref>]. All articles mentioned that the authors had no conflicts of interest. Although there are some unknown risks, the overall risk of bias in the included studies was low. The quality of the evidence was assessed according to the GRADE evidence profile (see Supplementary Materials). Among the analytical results of this study, the evidence level for 3 outcomes (pulmonary infection, wound infection, CHF) was judged to be high quality, the evidence quality for blood transfusion rate was low, and the evidence quality for the remaining outcomes was moderate. Common reasons for downgrading include publication bias and high heterogeneity. Overall, the level of evidence from this meta-analysis was moderate.</p><p id="Par24">
<fig id="Fig3"><label>Fig. 3</label><caption><p>Risk of bias summary</p></caption><graphic xlink:href="13018_2025_5883_Fig3_HTML" id="d33e1711"/></fig>
</p></sec><sec id="Sec14"><title>Results of meta-analysis</title><sec id="Sec15"><title>Infection</title><p id="Par25">Fourteen studies including 3207 patients [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR31">31</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR38">38</xref>&#x02013;<xref ref-type="bibr" rid="CR40">40</xref>] reported overall infection. Pooled analysis with a random effects model showed that the association between transfusion strategy and infection was not statistically significant (RR&#x02009;=&#x02009;0.81; 95% CI, 0.61&#x02013;1.07, <italic>P</italic>&#x02009;=&#x02009;0.14, <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;40%) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>A). Of these studies, 7 studies [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR38">38</xref>] (including 1206 patients) and 6 studies [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>](including 2854 patients) reported lung infection and wound infection, respectively. Pooled analysis of fixed-effects models showed that transfusion strategy had no effect on lung infection (RR, 0.80; 95% CI, 0.54&#x02013;1.18; <italic>P</italic>&#x02009;=&#x02009;0.26) and wound infection (RR, 1.06; 95% CI, 0.64&#x02013;1.19, <italic>P</italic>&#x02009;=&#x02009;0.16) without heterogeneity (<italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0%) (Fig.&#x000a0;<xref rid="Fig4" ref-type="fig">4</xref>B-C).</p><p id="Par26">
<fig id="Fig4"><label>Fig. 4</label><caption><p>Forest plots depicting the comparison between the restrictive blood transfusion (RBT) group and liberal blood transfusion (LBT) group: (<bold>A</bold>) Overall infection; (<bold>B</bold>) Lung infection; (<bold>C</bold>) Wound infection</p></caption><graphic xlink:href="13018_2025_5883_Fig4_HTML" id="d33e1828"/></fig>
</p></sec><sec id="Sec16"><title>Cardiovascular events</title><p id="Par27">Thirteen studies involving 4821 patients reported cardiovascular events [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. The meta-analysis results of the fixed effects model showed that RBT can significantly increase cardiovascular events compared with the LBT group without heterogeneity (RR&#x02009;=&#x02009;1.44; 95% CI: 1.15&#x02013;1.80, <italic>P</italic>&#x02009;=&#x02009;0.001; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0%) <bold>(</bold>Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>A<bold>)</bold>. Among these studies, 10 studies [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR40">40</xref>](including 4864 patients) and 5 studies [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR32">32</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR40">40</xref>](including 3333 patients) reported on MI and CHF, respectively. Pooled analysis of the fixed-effects model showed that compared with LBT, RBT increased the risk of MI (RR&#x02009;=&#x02009;1.70; 95% CI: 1.16&#x02013;2.48, <italic>P</italic>&#x02009;=&#x02009;0.006; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0%), but had no statistical significance for CHF (RR&#x02009;=&#x02009;1.04; 95% CI: 0.71&#x02013;1.52, <italic>P</italic>&#x02009;=&#x02009;0.85; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;2%) (Fig.&#x000a0;<xref rid="Fig5" ref-type="fig">5</xref>B-C).</p><p id="Par28">
<fig id="Fig5"><label>Fig. 5</label><caption><p>Forest plots depicting the comparison between the restrictive blood transfusion (RBT) group and liberal blood transfusion group: (<bold>A</bold>) Cardiovascular events; (<bold>B</bold>) Myocardial infarction; (<bold>C</bold>) Congestive heart failure</p></caption><graphic xlink:href="13018_2025_5883_Fig5_HTML" id="d33e1950"/></fig>
</p></sec><sec id="Sec17"><title>Thromboembolic events, cerebrovascular accidents, mortality, delirium, length of hospitalization, transfusion rates</title><p id="Par29">Thromboembolic events (RR&#x02009;=&#x02009;0.88; 95% CI: 0.33&#x02013;2.31, <italic>P</italic>&#x02009;=&#x02009;0.79; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0%), cerebrovascular accidents (RR&#x02009;=&#x02009;0.50; 95% CI: 0.09&#x02013;2.70, <italic>P</italic>&#x02009;=&#x02009;0.42; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0%), mortality (&#x02264;&#x02009;30 days) (RR&#x02009;=&#x02009;0.96; 95% CI: 0.87&#x02013;1.06, <italic>P</italic>&#x02009;=&#x02009;0.43; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;14%), mortality (&#x02265;&#x02009;60 days) (RR&#x02009;=&#x02009;0.94; 95% CI: 0.78&#x02013;1.15, <italic>P</italic>&#x02009;=&#x02009;0.57; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;0%), delirium (RR&#x02009;=&#x02009;1.33; 95% CI: 0.92&#x02013;1.93, <italic>P</italic>&#x02009;=&#x02009;0.13; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;34%) and length of hospitalization (RR = -0.08; 95% CI: -0.22-0.06, <italic>P</italic>&#x02009;=&#x02009;0.27; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;57%) were not statistically different between the RBT and LBT groups (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">1</xref>&#x02013;<xref rid="MOESM1" ref-type="media">6</xref>). Analysis of data from 14 trials [<xref ref-type="bibr" rid="CR17">17</xref>&#x02013;<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR36">36</xref>, <xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]involving 5102 patients showed that transfusion rates in the RBT group were significantly lower than those in the LBT with high heterogeneity (RR&#x02009;=&#x02009;0.70; 95% CI: 0.52&#x02013;0.94, <italic>P</italic>&#x02009;=&#x02009;0.02; <italic>I</italic><sup><italic>2</italic></sup>&#x02009;=&#x02009;97%) (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">7</xref>).</p></sec></sec><sec id="Sec18"><title>RBT (Threshold 7 to 8&#x000a0;g/dL) VS LBT (Threshold 9 to 10&#x000a0;g/dL)</title><p id="Par30">According to clinical practice, the RBT threshold is usually 7 to 8&#x000a0;g/dL and the LBT threshold is 9 to 10&#x000a0;g/dL [<xref ref-type="bibr" rid="CR1">1</xref>], and the two threshold ranges overlapped in included studies. Therefore, we only included nine studies within this common threshold for additional meta-analysis [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>, <xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR35">35</xref>, <xref ref-type="bibr" rid="CR40">40</xref>], and the results were consistent with the above results without significant difference. (Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">8</xref>&#x02013;<xref rid="MOESM1" ref-type="media">20</xref>).</p></sec><sec id="Sec19"><title>Subgroup analysis results</title><p id="Par31">Considering the characteristics of the included studies, the effect of transfusion strategy and the heterogeneity in the meta-analysis may be related to patient characteristics (patients at high risk for cardiovascular disease versus ordinary patients) and types of surgical procedures (total joint replacement or revision versus fracture repair). Therefore, we performed a subgroup analysis based on the above conditions and the results show that patient characteristics and types of surgical procedures do affect the meta-analysis results. The detailed results are shown in Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>. Of note, in patients at high risk for cardiovascular disease, RBT increase the risk of MI and length of hospitalization compared with LBT. Additionally, for joint replacement or revision surgery, RBTs were associated with lower overall infections and shorter length of hospitalization compared with LBT groups. For fracture repair surgery, RBT increases the risk of MI.</p><p id="Par32">
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Subgroup analysis evaluating transfusion strategies in orthopedic patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Variables</th><th align="left">Outcome</th><th align="left">Subgroup</th><th align="left">Number of Experiments</th><th align="left">Participants</th><th align="left">Statistical Method</th><th align="left">SMD [95% CI]/ RR [95% CI]</th><th align="left"><italic>P</italic> Value</th><th align="left" colspan="1"/></tr><tr><th align="left" colspan="6">Patient characteristics (patients at high risk for cardiovascular disease versus ordinary patients)</th><th align="left"/><th align="left"/><th align="left"/></tr></thead><tbody><tr><td align="left"/><td align="left">Overall infection</td><td align="left"/><td char="." align="char">14</td><td align="left">3207</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.82 [0.41, 1.64]</td><td align="left">0.14</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Patients at high risk for cardiovascular disease</td><td char="." align="char">2</td><td align="left">943</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.71 [0.29, 1.75]</td><td align="left">0.46</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Ordinary patients</td><td char="." align="char">12</td><td align="left">2264</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.81 [0.61, 1.07]</td><td align="left">0.16</td><td align="left"/></tr><tr><td align="left"/><td align="left">Cardiovascular events</td><td align="left"/><td char="." align="char">13</td><td align="left">4821</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.44 [1.15, 1.80]</td><td align="left">0.001</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Patients at high risk for cardiovascular disease</td><td char="." align="char">3</td><td align="left">2959</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.33 [1.02, 1.74]</td><td align="left">0.04</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Ordinary patients</td><td char="." align="char">10</td><td align="left">1862</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.74 [1.15, 2.63]</td><td align="left">0.008</td><td align="left"/></tr><tr><td align="left"/><td align="left">Myocardial infarction</td><td align="left"/><td char="." align="char">10</td><td align="left">3864</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.70 [1.16, 2.48]</td><td align="left">0.006</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Patients at high risk for cardiovascular disease</td><td char="." align="char">2</td><td align="left">2821</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.75 [1.17, 2.61]</td><td align="left">0.007</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Ordinary patients</td><td char="." align="char">8</td><td align="left">1043</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.34 [0.43, 4.23]</td><td align="left">0.61</td><td align="left"/></tr><tr><td align="left"/><td align="left">Congestive heart failure</td><td align="left"/><td char="." align="char">5</td><td align="left">3333</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.04 [0.71, 1.52]</td><td align="left">0.85</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Patients at high risk for cardiovascular disease</td><td char="." align="char">2</td><td align="left">2821</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.02 [0.68, 1.52]</td><td align="left">0.92</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Ordinary patients</td><td char="." align="char">3</td><td align="left">512</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.29 [0.32, 5.15]</td><td align="left">0.72</td><td align="left"/></tr><tr><td align="left"/><td align="left">Overall mortality (&#x02264;&#x02009;30 days)</td><td align="left"/><td char="." align="char">11</td><td align="left">6645</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.96 [0.87, 1.06]</td><td align="left">0.43</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Patients at high risk for cardiovascular disease</td><td char="." align="char">2</td><td align="left">2821</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.78 [0.57, 1.08]</td><td align="left">0.14</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Ordinary patients</td><td char="." align="char">9</td><td align="left">3824</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.99 [0.90, 1.10]</td><td align="left">0.88</td><td align="left"/></tr><tr><td align="left"/><td align="left">Overall mortality (&#x02265;&#x02009;60 days)</td><td align="left"/><td char="." align="char">5</td><td align="left">3367</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.94 [0.78, 1.15]</td><td align="left">0.57</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Patients at high risk for cardiovascular disease</td><td char="." align="char">2</td><td align="left">2821</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.83 [0.64, 1.08]</td><td align="left">0.17</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Ordinary patients</td><td char="." align="char">3</td><td align="left">546</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.16 [0.86, 1.56]</td><td align="left">0.34</td><td align="left"/></tr><tr><td align="left"/><td align="left">Transfusion rates</td><td align="left"/><td char="." align="char">14</td><td align="left">5102</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.70 [0.52, 0.94]</td><td align="left">0.02</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Patients at high risk for cardiovascular disease</td><td char="." align="char">3</td><td align="left">2959</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.62 [0.33, 1.16]</td><td align="left">0.14</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Ordinary patients</td><td char="." align="char">11</td><td align="left">2143</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.78 [0.55, 0.99]</td><td align="left">0.04</td><td align="left"/></tr><tr><td align="left"/><td align="left">Length of hospitalization</td><td align="left"/><td char="." align="char">7</td><td align="left">3296</td><td align="left">Std. Mean Difference (IV, Fixed, 95% CI)</td><td align="left">0.00 [-0.07, 0.07]</td><td align="left">0.96</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Patients at high risk for cardiovascular disease</td><td char="." align="char">2</td><td align="left">2154</td><td align="left">Std. Mean Difference (IV, Fixed, 95% CI)</td><td align="left">0.08 [-0.01, 0.16]</td><td align="left">0.07</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Ordinary patients</td><td char="." align="char">5</td><td align="left">1142</td><td align="left">Std. Mean Difference (IV, Fixed, 95% CI)</td><td align="left">-0.14 [-0.26, -0.03]</td><td align="left">0.02</td><td align="left"/></tr><tr><td align="left" colspan="6">
<bold>Surgical procedures (total joint replacement or revision versus fracture repair)</bold>
</td><td align="left"/><td align="left"/><td align="left"/></tr><tr><td align="left"/><td align="left">Overall infection</td><td align="left"/><td char="." align="char">14</td><td align="left">3207</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.81 [0.61, 1.07]</td><td align="left">0.14</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">4</td><td align="left">1137</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.63 [0.40, 0.97]</td><td align="left">0.04</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">10</td><td align="left">2070</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.92 [0.70, 1.21]</td><td align="left">0.54</td><td align="left"/></tr><tr><td align="left"/><td align="left">Wound infection</td><td align="left"/><td char="." align="char">6</td><td align="left">2854</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.64 [0.34, 1.19]</td><td align="left">0.16</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">2</td><td align="left">258</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.56 [0.12, 2.56]</td><td align="left">0.45</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">4</td><td align="left">2596</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.66 [0.33, 1.30]</td><td align="left">0.23</td><td align="left"/></tr><tr><td align="left"/><td align="left">Lung infection</td><td align="left"/><td char="." align="char">7</td><td align="left">1206</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.80 [0.54, 1.18]</td><td align="left">0.26</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">2</td><td align="left">258</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.47 [0.13, 1.63]</td><td align="left">0.23</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">5</td><td align="left">948</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.86 [0.57, 1.30]</td><td align="left">0.47</td><td align="left"/></tr><tr><td align="left"/><td align="left">Cardiovascular events</td><td align="left"/><td char="." align="char">13</td><td align="left">4821</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.44 [1.15, 1.80]</td><td align="left">0.001</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">3</td><td align="left">1006</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.64 [1.02, 2.62]</td><td align="left">0.04</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">10</td><td align="left">3815</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.39 [1.08, 1.79]</td><td align="left">0.01</td><td align="left"/></tr><tr><td align="left"/><td align="left">Myocardial infarction</td><td align="left"/><td char="." align="char">10</td><td align="left">3864</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.70 [1.16, 2.48]</td><td align="left">0.006</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">3</td><td align="left">579</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.73 [0.15, 3.63]</td><td align="left">0.70</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">7</td><td align="left">3285</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.79 [1.21, 2.65]</td><td align="left">0.004</td><td align="left"/></tr><tr><td align="left"/><td align="left">Overall mortality (&#x02264;&#x02009;30 days)</td><td align="left"/><td char="." align="char">11</td><td align="left">6645</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.96 [0.87, 1.06]</td><td align="left">0.43</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">2</td><td align="left">879</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.43 [0.06, 2.89]</td><td align="left">0.39</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">9</td><td align="left">5766</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">0.96 [0.87, 1.06]</td><td align="left">0.47</td><td align="left"/></tr><tr><td align="left"/><td align="left">Transfusion rates</td><td align="left"/><td char="." align="char">14</td><td align="left">5102</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.70 [0.52, 0.94]</td><td align="left">0.02</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">4</td><td align="left">1137</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.89 [0.70, 1.12]</td><td align="left">0.31</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">10</td><td align="left">3965</td><td align="left">Risk Ratio (M-H, Random, 95% CI)</td><td align="left">0.63 [0.43, 0.94]</td><td align="left">0.02</td><td align="left"/></tr><tr><td align="left"/><td align="left">Delirium</td><td align="left"/><td char="." align="char">5</td><td align="left">644</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.33 [0.92, 1.93]</td><td align="left">0.13</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">2</td><td align="left">319</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.13 [0.69, 1.86]</td><td align="left">0.62</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">3</td><td align="left">325</td><td align="left">Risk Ratio (M-H, Fixed, 95% CI)</td><td align="left">1.62 [0.92, 2.86]</td><td align="left">0.10</td><td align="left"/></tr><tr><td align="left"/><td align="left">Length of hospitalization</td><td align="left"/><td char="." align="char">7</td><td align="left">3296</td><td align="left">Std. Mean Difference (IV, Fixed, 95% CI)</td><td align="left">0.00 [-0.07, 0.07]</td><td align="left">0.96</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Total joint replacement or revision</td><td char="." align="char">3</td><td align="left">938</td><td align="left">Std. Mean Difference (IV, Fixed, 95% CI)</td><td align="left">-0.16 [-0.29, -0.03]</td><td align="left">0.01</td><td align="left"/></tr><tr><td align="left"/><td align="left"/><td align="left">Fracture repair</td><td char="." align="char">4</td><td align="left">2358</td><td align="left">Std. Mean Difference (IV, Fixed, 95% CI)</td><td align="left">0.07 [-0.02, 0.15]</td><td align="left">0.11</td><td align="left"/></tr></tbody></table><table-wrap-foot><p>Abbreviation: RR, risk ratio; SMD, standardized mean difference</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec20"><title>Sensitivity analysis and publication bias</title><p id="Par33">The results of sensitivity analysis and publication bias are shown in Table&#x000a0;<xref rid="Tab4" ref-type="table">4</xref>. The results obtained by the sensitivity analysis were basically consistent with the results of all included studies, indicating that our results are stable (See Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">21</xref>&#x02013;<xref rid="MOESM1" ref-type="media">24</xref>). However, only overall infection, lung infection and cerebrovascular accident did not show publication bias in Egger&#x02019;s test (<italic>p</italic>&#x02009;&#x0003c;&#x02009;0.05). The remaining results were analyzed using the trim and fill method (Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>). Wound infection, CHF, delirium, and length of hospitalization were not trimmed, and the data in the funnel plot remained unchanged, indicating that there was no significant publication bias for these outcomes.</p><p id="Par34">
<table-wrap id="Tab4"><label>Table 4</label><caption><p>Sensitivity and publication bias analysis</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Outcome</th><th align="left">SMD/RR fluctuation</th><th align="left">95% CI fluctuation</th><th align="left">Publication bias (<italic>P</italic> value)</th><th align="left">Pooling model</th></tr></thead><tbody><tr><td align="left">Overall infection</td><td char="." align="char">0.69&#x02013;0.89</td><td char="." align="char">0.47&#x02013;1.15</td><td char="." align="char">0.001</td><td align="left">Random (I-V heterogeneity)</td></tr><tr><td align="left">Lung infection</td><td char="." align="char">0.50&#x02013;0.92</td><td char="." align="char">0.22&#x02013;1.38</td><td char="." align="char">0.013</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Wound infection</td><td char="." align="char">0.57&#x02013;0.78</td><td char="." align="char">0.29&#x02013;2.12</td><td char="." align="char">0.96</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Cardiovascular Events</td><td char="." align="char">1.39&#x02013;1.51</td><td char="." align="char">1.02&#x02013;1.96</td><td char="." align="char">0.407</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Myocardial infarction</td><td char="." align="char">1.61&#x02013;1.80</td><td char="." align="char">1.00-3.22</td><td char="." align="char">0.652</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Congestive heart failure</td><td char="." align="char">0.70&#x02013;1.28</td><td char="." align="char">0.37&#x02013;1.57</td><td char="." align="char">0.981</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Thromboembolic Events</td><td char="." align="char">0.76&#x02013;1.18</td><td char="." align="char">0.22&#x02013;3.79</td><td char="." align="char">0.518</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Cerebrovascular Accidents</td><td char="." align="char">0.33&#x02013;0.63</td><td char="." align="char">0.04&#x02013;5.02</td><td char="." align="char">0.019</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Mortality (&#x02264;&#x02009;30 days)</td><td char="." align="char">0.94-1.00</td><td char="." align="char">0.76&#x02013;1.3</td><td char="." align="char">0.31</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Mortality (&#x02265;&#x02009;60 days)</td><td char="." align="char">0.87&#x02013;1.02</td><td char="." align="char">0.70&#x02013;1.31</td><td char="." align="char">0.574</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Transfusion rates</td><td char="." align="char">0.67&#x02013;0.73</td><td char="." align="char">0.51&#x02013;0.97</td><td char="." align="char">0.883</td><td align="left">Random (I-V heterogeneity)</td></tr><tr><td align="left">Delirium</td><td char="." align="char">1.05&#x02013;1.80</td><td char="." align="char">0.67&#x02013;3.1</td><td char="." align="char">0.758</td><td align="left">Fixed Inverse Variance</td></tr><tr><td align="left">Length of hospitalization</td><td char="." align="char">(-0.13)-(0.00)</td><td char="." align="char">(-0.26)-(0.09)</td><td char="." align="char">0.085</td><td align="left">Random (I-V heterogeneity)</td></tr></tbody></table><table-wrap-foot><p>Abbreviation: RR, risk ratio; SMD, standardized mean difference</p></table-wrap-foot></table-wrap>
</p></sec><sec id="Sec21"><title>Trial sequential analysis</title><p id="Par35">TSA can assess whether the cumulative effect of studies included in a meta-analysis is supported by sufficient data. TSA results indicate that there is sufficient data to draw definite conclusions about the impact of transfusion strategies on transfusion rates and overall mortality (&#x02265;&#x02009;60 days). However, the evidence for efficacy for the remaining outcomes analyzed (including infection, cardiovascular events, thromboembolic events, cerebrovascular accidents, mortality, delirium, length of hospitalization) was inconclusive. In other words, the currently accumulated number of clinical trial participants is too small, which may lead to insufficient conclusions in this meta-analysis. Therefore, more high-quality clinical trials with large populations can be conducted in the future to further verify these conclusions (Fig.&#x000a0;<xref rid="Fig6" ref-type="fig">6</xref> and Supplementary Fig.&#x000a0;<xref rid="MOESM1" ref-type="media">25</xref>).</p><p id="Par36">
<fig id="Fig6"><label>Fig. 6</label><caption><p>Trial sequential analysis. A required information size was calculated based on using &#x003b1;&#x02009;=&#x02009;0.05 (two-sided), &#x003b2;&#x02009;=&#x02009;0.20 (power 80%), and an anticipated relative risk reduction (RRR) of 20%. (<bold>A</bold>) Overall infection; (<bold>B</bold>) Cardiovascular events; (<bold>C</bold>) Transfusion rates; (<bold>D</bold>) Mortality (&#x02265;&#x02009;60 days)</p></caption><graphic xlink:href="13018_2025_5883_Fig6_HTML" id="d33e3211"/></fig>
</p></sec></sec><sec id="Sec22"><title>Discussion</title><sec id="Sec23"><title>Principal findings</title><p id="Par37">This meta-analysis included 19 studies involving a total of 7833 patients. The risk of bias in the included studies was low, and the overall analysis results were of moderate quality of evidence. The results show that compared with the LBT strategy, the RBT strategy can increase the occurrence of cardiovascular events, which mainly increases MI rather than CHF. In addition, the blood transfusion rate in the RBT group was higher than that in the LBT group, but there was no difference in the impact of RBT strategies and LBT strategies on infection, thromboembolic events, cerebrovascular accidents, delirium, length of hospitalization and mortality. The results of the subgroup analysis showed that whether the patient was at risk for cardiovascular disease and the type of surgery were important factors affecting the adverse reactions of the blood transfusion strategy. The TSA results showed that except for the results of transfusion rates and overall mortality (&#x02265;&#x02009;60 days), which were supported by sufficient evidence, the other results were inconclusive due to the small sample size.</p><p id="Par38">Blood transfusions are associated with numerous complications, such as transfusion-related lung injury, cardiac overload, immune responses, and infectious diseases [<xref ref-type="bibr" rid="CR41">41</xref>&#x02013;<xref ref-type="bibr" rid="CR43">43</xref>]. Blood transfusions have been shown to be strongly associated with recurrent thrombosis and death in patients with acute coronary syndrome and/or MI [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. In the clinical studies we included, we found that most of the patients undergoing orthopedic surgery are elderly and cannot tolerate a hypoxic environment. Excessive blood transfusion or excessive fluid delivery can easily lead to fluid circulation overload and increase the burden on the heart. These may increase the probability of adverse transfusion reactions.</p><p id="Par39">Transfusion-associated circulatory overload (TACO) is the most common pulmonary complication of transfusion and the leading cause of transfusion-related death [<xref ref-type="bibr" rid="CR1">1</xref>]. Among our included studies, one study reported one case of TACO in the restricted group [<xref ref-type="bibr" rid="CR17">17</xref>], and another reported five cases of TACO (but the transfusion method was unknown [<xref ref-type="bibr" rid="CR29">29</xref>].</p></sec><sec id="Sec24"><title>Comparison with existing literature</title><p id="Par40">In 2015, Brunskill et al. [<xref ref-type="bibr" rid="CR11">11</xref>] conducted a meta-analysis to evaluate the benefits and harms of RBC transfusion strategies in patients undergoing hip fracture surgery. They included six trials (2722 participants) that showed a reduced risk of MI but no difference in thromboembolism, wound infection, CHF and mortality in LBT groups compared with RBT groups, which were also consistent with our findings. Wang et al. [<xref ref-type="bibr" rid="CR16">16</xref>] and Mitchell et al. [<xref ref-type="bibr" rid="CR14">14</xref>] reported no statistically significant relationship between blood transfusion strategy and infections in orthopedic patients, but Teng&#x02019;s study found that a RBT strategy could significantly reduce infections [<xref ref-type="bibr" rid="CR15">15</xref>]. Mao et al. [<xref ref-type="bibr" rid="CR13">13</xref>] found that the blood transfusion strategy did not affect the incidence of MI. These differences may be due to the small number of included studies and the different effect models used. Different from previously published meta-analyses on the same topic, our article systematically screened and updated the literature and included more RCTs. The most recent meta that has been published so far was searched in July 2019, and only studied the relationship between blood transfusion and infection rates [<xref ref-type="bibr" rid="CR16">16</xref>]. Most existing studies have only searched for hip and knee surgeries. We searched for all orthopedic-related surgeries and also studied the relationship between transfusion strategies and various outcome measures. We also analyzed the relationship between different subgroups. Therefore, our research is a necessary update and improvement of previous research.</p></sec><sec id="Sec25"><title>Strengths of this meta-analysis</title><p id="Par41">First, this article is a comprehensive updated meta-analysis. It conducted a comprehensive and detailed literature search and screening, included a larger number of studies and participants, and covered studies published from 1998 to 2024 (4/19 of them were published in the last 3 years). Second, the low heterogeneity of the meta-analysis, the good consistency of the sensitivity analysis, the low risk of bias and the moderate quality of evidence all suggest that our analysis results are stable and reliable. Third, compared with the recently published meta-analysis on the same topic, we updated RCTs in the past 5 years and included multiple outcomes such as cardiovascular events, thromboembolic events, mortality, delirium, length of hospitalization, etc. This has important implications for updating the latest research results and comprehensively comparing the impact of transfusion strategies on orthopedic patients. Fourth, we used TSA to evaluate the adequacy of the results, which has not been used in previously published articles on the same topic. Fifth, the studies included in this article are of higher quality evidence from RCTs, and compared with cross-sectional studies and cohort studies, some confounding factors have been controlled.</p></sec><sec id="Sec26"><title>Limitations</title><p id="Par42">Our study has several limitations. Since the existing RCTs do not provide detailed individual patient data and blood transfusion conditions, we are unable to analyze the impact of blood transfusion strategies on different factors such as patient age, underlying diseases, gender, and disease type. The amount, type, suspension, and leucocyte information of RBCs used for transfusion were not clearly reported, and these differences in transfusion strategies may also be a source of part of the heterogeneity. Egger test and trim-and-fill analysis showed that some outcomes had a certain publication bias, which may be related to the small number of RCTs reporting this outcome. In addition, the blood transfusion process may be accompanied by the use of some drugs or interventions to reduce blood loss, RBC requirements and infection rates, such as perioperative iron and erythropoietin supplementation, which our article did not consider.</p></sec><sec id="Sec27"><title>Implications for clinical practice and research</title><p id="Par43">Our analysis found that RBT reduce transfusion rates but may increase the risk of cardiovascular events (mainly MI), especially in patients at high risk for cardiovascular disease. Furthermore, RBT have varying effects in different orthopedic surgeries. Therefore, we need to be cautious about blood transfusions in clinical practice, and comprehensively consider patient characteristics and surgery types when making decisions. TACO and transfusion-related acute lung injury (TRALI), the main cause of death among blood transfusion associated complications, refer to acute respiratory distress syndrome occurring within 6&#x000a0;h after blood transfusion [<xref ref-type="bibr" rid="CR1">1</xref>]. These two are the dominant factors in weighing the risks of transfusion, but they are rarely reported in the included studies and deserve attention in future studies. In the future, we also hope that more research will be done to analyze the mechanism of adverse reactions caused by blood transfusion strategies in order to come up with countermeasures.</p></sec></sec><sec id="Sec28"><title>Conclusion</title><p id="Par44">This meta-analysis compared the effects of blood transfusion strategies in orthopedic patients using outcome measures such as infection, cardiovascular events, cerebrovascular accidents, and mortality. The overall results indicate that the RBT strategy increases the risk of cardiovascular events (mainly MI) and reduces transfusion rates, but has no statistically significant effect on other outcome measures. The patient&#x02019;s cardiovascular disease risk and type of surgery also influence the outcome of the transfusion strategy. Potential differences between RBT and LBT strategies remain to be explored in larger, higher-quality clinical trials.</p></sec><sec id="Sec29" sec-type="supplementary-material"><title>Electronic supplementary material</title><p>Below is the link to the electronic supplementary material.</p><p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="13018_2025_5883_MOESM1_ESM.docx"><caption><p>Supplementary Material 1</p></caption></media></supplementary-material>
</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn><fn><p>Zhou Zhou, Zefeng Xiao and Yan Luo contributed equally to this work and share first authorship.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Author contributions</title><p>Conception and Design of the study: XL.X. and TB.N.; Writing, Review and Editing the manuscript: Y.L., Z.Z. and ZF.X.; Analyzed and interpreted the data: Y.L.; Researched the data: Y.L., Z.Z. and ZF.X; Wrote, Read and Approved the final manuscript: All authors.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This project was supported by the Hunan Provincial Health Commission Foundation (Grant No. D202315027975).</p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par45">Not applicable.</p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par46">Not applicable.</p></notes><notes id="FPar5"><title>Footnotes</title><p id="Par47">Not applicable.</p></notes><notes id="FPar6"><title>PROSPERO registration no</title><p id="Par48">CRD42024604868.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par49">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>JL</given-names></name><name><surname>Stanworth</surname><given-names>SJ</given-names></name><name><surname>Guyatt</surname><given-names>G</given-names></name><name><surname>Valentine</surname><given-names>S</given-names></name><name><surname>Dennis</surname><given-names>J</given-names></name><name><surname>Bakhtary</surname><given-names>S</given-names></name><etal/></person-group><source>Red Blood Cell Transfusion: 2023 AABB Int Guidelines JAMA</source><year>2023</year><volume>330</volume><issue>19</issue><fpage>1892</fpage><lpage>902</lpage></element-citation><mixed-citation id="mc-CR1" publication-type="journal">Carson JL, Stanworth SJ, Guyatt G, Valentine S, Dennis J, Bakhtary S, et al. Red Blood Cell Transfusion: 2023 AABB Int Guidelines JAMA. 2023;330(19):1892&#x02013;902.</mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>JM</given-names></name><name><surname>Sapiano</surname><given-names>MRP</given-names></name><name><surname>Mowla</surname><given-names>S</given-names></name><name><surname>Bota</surname><given-names>D</given-names></name><name><surname>Berger</surname><given-names>JJ</given-names></name><name><surname>Basavaraju</surname><given-names>SV</given-names></name></person-group><article-title>Has the trend of declining blood transfusions in the united States ended? Findings of the 2019 National blood collection and utilization survey</article-title><source>Transfusion</source><year>2021</year><volume>61</volume><issue>Suppl 2</issue><fpage>S1</fpage><lpage>10</lpage><pub-id pub-id-type="pmid">34165191</pub-id>
</element-citation><mixed-citation id="mc-CR2" publication-type="journal">Jones JM, Sapiano MRP, Mowla S, Bota D, Berger JJ, Basavaraju SV. Has the trend of declining blood transfusions in the united States ended? Findings of the 2019 National blood collection and utilization survey. Transfusion. 2021;61(Suppl 2):S1&#x02013;10.<pub-id pub-id-type="pmid">34165191</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Franchini</surname><given-names>M</given-names></name><name><surname>Marano</surname><given-names>G</given-names></name><name><surname>Mengoli</surname><given-names>C</given-names></name><name><surname>Pupella</surname><given-names>S</given-names></name><name><surname>Vaglio</surname><given-names>S</given-names></name><name><surname>Munoz</surname><given-names>M</given-names></name><etal/></person-group><article-title>Red blood cell transfusion policy: a critical literature review</article-title><source>Blood Transfus</source><year>2017</year><volume>15</volume><issue>4</issue><fpage>307</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">28661855</pub-id>
</element-citation><mixed-citation id="mc-CR3" publication-type="journal">Franchini M, Marano G, Mengoli C, Pupella S, Vaglio S, Munoz M, et al. Red blood cell transfusion policy: a critical literature review. Blood Transfus. 2017;15(4):307&#x02013;17.<pub-id pub-id-type="pmid">28661855</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><collab>American Society of Anesthesiologists Task Force on Perioperative Blood M</collab></person-group><article-title>Practice guidelines for perioperative blood management: an updated report by the American society of anesthesiologists task force on perioperative blood management**</article-title><source>Anesthesiology</source><year>2015</year><volume>122</volume><issue>2</issue><fpage>241</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1097/ALN.0000000000000463</pub-id><pub-id pub-id-type="pmid">25545654</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">American Society of Anesthesiologists Task Force on Perioperative Blood M. Practice guidelines for perioperative blood management: an updated report by the American society of anesthesiologists task force on perioperative blood management**. Anesthesiology. 2015;122(2):241&#x02013;75.<pub-id pub-id-type="pmid">25545654</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name><surname>Klein</surname><given-names>AA</given-names></name><name><surname>Arnold</surname><given-names>P</given-names></name><name><surname>Bingham</surname><given-names>RM</given-names></name><name><surname>Brohi</surname><given-names>K</given-names></name><name><surname>Clark</surname><given-names>R</given-names></name><name><surname>Collis</surname><given-names>R</given-names></name><etal/></person-group><article-title>AAGBI guidelines: the use of blood components and their alternatives 2016</article-title><source>Anaesthesia</source><year>2016</year><volume>71</volume><issue>7</issue><fpage>829</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1111/anae.13489</pub-id><pub-id pub-id-type="pmid">27062274</pub-id>
</element-citation><mixed-citation id="mc-CR5" publication-type="journal">Klein AA, Arnold P, Bingham RM, Brohi K, Clark R, Collis R, et al. AAGBI guidelines: the use of blood components and their alternatives 2016. Anaesthesia. 2016;71(7):829&#x02013;42.<pub-id pub-id-type="pmid">27062274</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Moras</surname><given-names>E</given-names></name><name><surname>Abbott</surname><given-names>JD</given-names></name><name><surname>Vallabhajosyula</surname><given-names>S</given-names></name></person-group><article-title>AABB recommends restrictive RBC transfusions for hospitalized adults and children</article-title><source>Ann Intern Med</source><year>2024</year><volume>177</volume><issue>2</issue><fpage>JC14</fpage><pub-id pub-id-type="doi">10.7326/J23-0116</pub-id><pub-id pub-id-type="pmid">38316008</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Moras E, Abbott JD, Vallabhajosyula S. AABB recommends restrictive RBC transfusions for hospitalized adults and children. Ann Intern Med. 2024;177(2):JC14.<pub-id pub-id-type="pmid">38316008</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Mueller MM, Van Remoortel H, Meybohm P, Aranko K, Aubron C, Burger R et al. Patient Blood Management: Recommendations From the 2018 Frankfurt Consensus Conference. JAMA. 2019;321(10):983&#x02013;&#x02009;97.</mixed-citation></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Tibi</surname><given-names>P</given-names></name><name><surname>McClure</surname><given-names>RS</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>RA</given-names></name><name><surname>Fitzgerald</surname><given-names>D</given-names></name><name><surname>Mazer</surname><given-names>CD</given-names></name><etal/></person-group><article-title>STS/SCA/AmSECT/SABM update to the clinical practice guidelines on patient blood management</article-title><source>Ann Thorac Surg</source><year>2021</year><volume>112</volume><issue>3</issue><fpage>981</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2021.03.033</pub-id><pub-id pub-id-type="pmid">34217505</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Tibi P, McClure RS, Huang J, Baker RA, Fitzgerald D, Mazer CD, et al. STS/SCA/AmSECT/SABM update to the clinical practice guidelines on patient blood management. Ann Thorac Surg. 2021;112(3):981&#x02013;1004.<pub-id pub-id-type="pmid">34217505</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name><surname>Hendrickson</surname><given-names>JE</given-names></name><name><surname>Roubinian</surname><given-names>NH</given-names></name><name><surname>Chowdhury</surname><given-names>D</given-names></name><name><surname>Brambilla</surname><given-names>D</given-names></name><name><surname>Murphy</surname><given-names>EL</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication</article-title><source>Transfusion</source><year>2016</year><volume>56</volume><issue>10</issue><fpage>2587</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1111/trf.13730</pub-id><pub-id pub-id-type="pmid">27460200</pub-id>
</element-citation><mixed-citation id="mc-CR9" publication-type="journal">Hendrickson JE, Roubinian NH, Chowdhury D, Brambilla D, Murphy EL, Wu Y, et al. Incidence of transfusion reactions: a multicenter study utilizing systematic active surveillance and expert adjudication. Transfusion. 2016;56(10):2587&#x02013;96.<pub-id pub-id-type="pmid">27460200</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Vuille-Lessard</surname><given-names>E</given-names></name><name><surname>Boudreault</surname><given-names>D</given-names></name><name><surname>Girard</surname><given-names>F</given-names></name><name><surname>Ruel</surname><given-names>M</given-names></name><name><surname>Chagnon</surname><given-names>M</given-names></name><name><surname>Hardy</surname><given-names>JF</given-names></name></person-group><article-title>Red blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study</article-title><source>Transfusion</source><year>2010</year><volume>50</volume><issue>10</issue><fpage>2117</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2010.02697.x</pub-id><pub-id pub-id-type="pmid">20492612</pub-id>
</element-citation><mixed-citation id="mc-CR10" publication-type="journal">Vuille-Lessard E, Boudreault D, Girard F, Ruel M, Chagnon M, Hardy JF. Red blood cell transfusion practice in elective orthopedic surgery: a multicenter cohort study. Transfusion. 2010;50(10):2117&#x02013;24.<pub-id pub-id-type="pmid">20492612</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Brunskill</surname><given-names>SJ</given-names></name><name><surname>Millette</surname><given-names>SL</given-names></name><name><surname>Shokoohi</surname><given-names>A</given-names></name><name><surname>Pulford</surname><given-names>EC</given-names></name><name><surname>Doree</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>MF</given-names></name><etal/></person-group><article-title>Red blood cell transfusion for people undergoing hip fracture surgery</article-title><source>Cochrane Database Syst Rev</source><year>2015</year><volume>2015</volume><issue>4</issue><fpage>CD009699</fpage><pub-id pub-id-type="pmid">25897628</pub-id>
</element-citation><mixed-citation id="mc-CR11" publication-type="journal">Brunskill SJ, Millette SL, Shokoohi A, Pulford EC, Doree C, Murphy MF, et al. Red blood cell transfusion for people undergoing hip fracture surgery. Cochrane Database Syst Rev. 2015;2015(4):CD009699.<pub-id pub-id-type="pmid">25897628</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Gu</surname><given-names>WJ</given-names></name><name><surname>Gu</surname><given-names>XP</given-names></name><name><surname>Wu</surname><given-names>XD</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Kwong</surname><given-names>JSW</given-names></name><name><surname>Zhou</surname><given-names>LY</given-names></name><etal/></person-group><article-title>Restrictive versus Liberal strategy for red Blood-Cell transfusion: A systematic review and Meta-Analysis in orthopaedic patients</article-title><source>J Bone Joint Surg Am</source><year>2018</year><volume>100</volume><issue>8</issue><fpage>686</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.2106/JBJS.17.00375</pub-id><pub-id pub-id-type="pmid">29664857</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Gu WJ, Gu XP, Wu XD, Chen H, Kwong JSW, Zhou LY, et al. Restrictive versus Liberal strategy for red Blood-Cell transfusion: A systematic review and Meta-Analysis in orthopaedic patients. J Bone Joint Surg Am. 2018;100(8):686&#x02013;95.<pub-id pub-id-type="pmid">29664857</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Mao</surname><given-names>T</given-names></name><name><surname>Gao</surname><given-names>F</given-names></name><name><surname>Han</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>W</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Restrictive versus Liberal transfusion strategies for red blood cell transfusion after hip or knee surgery: A systematic review and meta-analysis</article-title><source>Med (Baltim)</source><year>2017</year><volume>96</volume><issue>25</issue><fpage>e7326</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000007326</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Mao T, Gao F, Han J, Sun W, Guo W, Li Z, et al. Restrictive versus Liberal transfusion strategies for red blood cell transfusion after hip or knee surgery: A systematic review and meta-analysis. Med (Baltim). 2017;96(25):e7326.</mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>MD</given-names></name><name><surname>Betesh</surname><given-names>JS</given-names></name><name><surname>Ahn</surname><given-names>J</given-names></name><name><surname>Hume</surname><given-names>EL</given-names></name><name><surname>Mehta</surname><given-names>S</given-names></name><name><surname>Umscheid</surname><given-names>CA</given-names></name></person-group><article-title>Transfusion thresholds for major orthopedic surgery: A systematic review and Meta-analysis</article-title><source>J Arthroplasty</source><year>2017</year><volume>32</volume><issue>12</issue><fpage>3815</fpage><lpage>21</lpage><pub-id pub-id-type="doi">10.1016/j.arth.2017.06.054</pub-id><pub-id pub-id-type="pmid">28735803</pub-id>
</element-citation><mixed-citation id="mc-CR14" publication-type="journal">Mitchell MD, Betesh JS, Ahn J, Hume EL, Mehta S, Umscheid CA. Transfusion thresholds for major orthopedic surgery: A systematic review and Meta-analysis. J Arthroplasty. 2017;32(12):3815&#x02013;21.<pub-id pub-id-type="pmid">28735803</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Teng</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wei</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Du</surname><given-names>S</given-names></name><etal/></person-group><article-title>Restrictive blood transfusion strategies and associated infection in orthopedic patients: a meta-analysis of 8 randomized controlled trials</article-title><source>Sci Rep</source><year>2015</year><volume>5</volume><fpage>13421</fpage><pub-id pub-id-type="doi">10.1038/srep13421</pub-id><pub-id pub-id-type="pmid">26306601</pub-id>
</element-citation><mixed-citation id="mc-CR15" publication-type="journal">Teng Z, Zhu Y, Liu Y, Wei G, Wang S, Du S, et al. Restrictive blood transfusion strategies and associated infection in orthopedic patients: a meta-analysis of 8 randomized controlled trials. Sci Rep. 2015;5:13421.<pub-id pub-id-type="pmid">26306601</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name></person-group><article-title>Liberal blood transfusion strategies and associated infection in orthopedic patients: A meta-analysis</article-title><source>Med (Baltim)</source><year>2021</year><volume>100</volume><issue>10</issue><fpage>e24430</fpage><pub-id pub-id-type="doi">10.1097/MD.0000000000024430</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Wang Y, Chen J, Yang Z, Liu Y. Liberal blood transfusion strategies and associated infection in orthopedic patients: A meta-analysis. Med (Baltim). 2021;100(10):e24430.</mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Gillies</surname><given-names>MA</given-names></name><name><surname>Ghaffar</surname><given-names>S</given-names></name><name><surname>Moppett</surname><given-names>IK</given-names></name><name><surname>Docherty</surname><given-names>AB</given-names></name><name><surname>Clarke</surname><given-names>S</given-names></name><name><surname>Rea</surname><given-names>N</given-names></name><etal/></person-group><article-title>A restrictive versus Liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF)</article-title><source>Br J Anaesth</source><year>2021</year><volume>126</volume><issue>1</issue><fpage>77</fpage><lpage>86</lpage><pub-id pub-id-type="doi">10.1016/j.bja.2020.06.048</pub-id><pub-id pub-id-type="pmid">32703548</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Gillies MA, Ghaffar S, Moppett IK, Docherty AB, Clarke S, Rea N, et al. A restrictive versus Liberal transfusion strategy to prevent myocardial injury in patients undergoing surgery for fractured neck of femur: a feasibility randomised trial (RESULT-NOF). Br J Anaesth. 2021;126(1):77&#x02013;86.<pub-id pub-id-type="pmid">32703548</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Mullis</surname><given-names>BH</given-names></name><name><surname>Mullis</surname><given-names>LS</given-names></name><name><surname>Kempton</surname><given-names>LB</given-names></name><name><surname>Virkus</surname><given-names>W</given-names></name><name><surname>Slaven</surname><given-names>JE</given-names></name><name><surname>Bruggers</surname><given-names>J</given-names></name></person-group><article-title>Early results of orthopaedic trauma and anemia: Conservative versus Liberal transfusion strategy</article-title><source>J Am Acad Orthop Surg</source><year>2024</year><volume>32</volume><issue>5</issue><fpage>228</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.5435/JAAOS-D-23-00235</pub-id><pub-id pub-id-type="pmid">38154083</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Mullis BH, Mullis LS, Kempton LB, Virkus W, Slaven JE, Bruggers J. Early results of orthopaedic trauma and anemia: Conservative versus Liberal transfusion strategy. J Am Acad Orthop Surg. 2024;32(5):228&#x02013;35.<pub-id pub-id-type="pmid">38154083</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Mullis</surname><given-names>BH</given-names></name><name><surname>Mullis</surname><given-names>LS</given-names></name><name><surname>Kempton</surname><given-names>LB</given-names></name><name><surname>Virkus</surname><given-names>W</given-names></name><name><surname>Slaven</surname><given-names>JE</given-names></name><name><surname>Bruggers</surname><given-names>J</given-names></name></person-group><article-title>Orthopaedic trauma and anemia: Conservative versus Liberal transfusion strategy: A prospective randomized study</article-title><source>J Orthop Trauma</source><year>2024</year><volume>38</volume><issue>1</issue><fpage>18</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1097/BOT.0000000000002696</pub-id><pub-id pub-id-type="pmid">38093439</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Mullis BH, Mullis LS, Kempton LB, Virkus W, Slaven JE, Bruggers J. Orthopaedic trauma and anemia: Conservative versus Liberal transfusion strategy: A prospective randomized study. J Orthop Trauma. 2024;38(1):18&#x02013;24.<pub-id pub-id-type="pmid">38093439</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Quaranta</surname><given-names>M</given-names></name><name><surname>Miranda</surname><given-names>L</given-names></name><name><surname>Oliva</surname><given-names>F</given-names></name><name><surname>Migliorini</surname><given-names>F</given-names></name><name><surname>Pezzuti</surname><given-names>G</given-names></name><name><surname>Maffulli</surname><given-names>N</given-names></name></person-group><article-title>Haemoglobin and transfusions in elderly patients with hip fractures: the effect of a dedicated orthogeriatrician</article-title><source>J Orthop Surg Res</source><year>2021</year><volume>16</volume><issue>1</issue><fpage>387</fpage><pub-id pub-id-type="doi">10.1186/s13018-021-02524-0</pub-id><pub-id pub-id-type="pmid">34134743</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Quaranta M, Miranda L, Oliva F, Migliorini F, Pezzuti G, Maffulli N. Haemoglobin and transfusions in elderly patients with hip fractures: the effect of a dedicated orthogeriatrician. J Orthop Surg Res. 2021;16(1):387.<pub-id pub-id-type="pmid">34134743</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Page</surname><given-names>MJ</given-names></name><name><surname>McKenzie</surname><given-names>JE</given-names></name><name><surname>Bossuyt</surname><given-names>PM</given-names></name><name><surname>Boutron</surname><given-names>I</given-names></name><name><surname>Hoffmann</surname><given-names>TC</given-names></name><name><surname>Mulrow</surname><given-names>CD</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.<pub-id pub-id-type="pmid">33782057</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Shea</surname><given-names>BJ</given-names></name><name><surname>Reeves</surname><given-names>BC</given-names></name><name><surname>Wells</surname><given-names>G</given-names></name><name><surname>Thuku</surname><given-names>M</given-names></name><name><surname>Hamel</surname><given-names>C</given-names></name><name><surname>Moran</surname><given-names>J</given-names></name><etal/></person-group><article-title>AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both</article-title><source>BMJ</source><year>2017</year><volume>358</volume><fpage>j4008</fpage><pub-id pub-id-type="doi">10.1136/bmj.j4008</pub-id><pub-id pub-id-type="pmid">28935701</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.<pub-id pub-id-type="pmid">28935701</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Duval</surname><given-names>S</given-names></name><name><surname>Tweedie</surname><given-names>R</given-names></name></person-group><article-title>Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis</article-title><source>Biometrics</source><year>2000</year><volume>56</volume><issue>2</issue><fpage>455</fpage><lpage>63</lpage><pub-id pub-id-type="doi">10.1111/j.0006-341X.2000.00455.x</pub-id><pub-id pub-id-type="pmid">10877304</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics. 2000;56(2):455&#x02013;63.<pub-id pub-id-type="pmid">10877304</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Huang</surname><given-names>B</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Xu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name></person-group><article-title>Effects and safety of hyaluronic acid gel on intrauterine adhesion and fertility after intrauterine surgery: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials</article-title><source>Am J Obstet Gynecol</source><year>2024</year><volume>231</volume><issue>1</issue><fpage>36</fpage><lpage>5035</lpage><pub-id pub-id-type="doi">10.1016/j.ajog.2023.12.039</pub-id><pub-id pub-id-type="pmid">38191020</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Luo Y, Sun Y, Huang B, Chen J, Xu B, Li H. Effects and safety of hyaluronic acid gel on intrauterine adhesion and fertility after intrauterine surgery: a systematic review and meta-analysis with trial sequential analysis of randomized controlled trials. Am J Obstet Gynecol. 2024;231(1):36&#x02013;5035.<pub-id pub-id-type="pmid">38191020</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><label>25.</label><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>JL</given-names></name><name><surname>Terrin</surname><given-names>ML</given-names></name><name><surname>Barton</surname><given-names>FB</given-names></name><name><surname>Aaron</surname><given-names>R</given-names></name><name><surname>Greenburg</surname><given-names>AG</given-names></name><name><surname>Heck</surname><given-names>DA</given-names></name><etal/></person-group><article-title>A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture</article-title><source>Transfusion</source><year>1998</year><volume>38</volume><issue>6</issue><fpage>522</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1046/j.1537-2995.1998.38698326331.x</pub-id><pub-id pub-id-type="pmid">9661685</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Carson JL, Terrin ML, Barton FB, Aaron R, Greenburg AG, Heck DA, et al. A pilot randomized trial comparing symptomatic vs. hemoglobin-level-driven red blood cell transfusions following hip fracture. Transfusion. 1998;38(6):522&#x02013;9.<pub-id pub-id-type="pmid">9661685</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><label>26.</label><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Lotke</surname><given-names>PA</given-names></name><name><surname>Barth</surname><given-names>P</given-names></name><name><surname>Garino</surname><given-names>JP</given-names></name><name><surname>Cook</surname><given-names>ER</given-names></name></person-group><article-title>Predonated autologous blood transfusions after total knee arthroplasty: immediate versus delayed administration</article-title><source>J Arthroplasty</source><year>1999</year><volume>14</volume><issue>6</issue><fpage>647</fpage><lpage>50</lpage><pub-id pub-id-type="doi">10.1016/S0883-5403(99)90216-4</pub-id><pub-id pub-id-type="pmid">10512433</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Lotke PA, Barth P, Garino JP, Cook ER. Predonated autologous blood transfusions after total knee arthroplasty: immediate versus delayed administration. J Arthroplasty. 1999;14(6):647&#x02013;50.<pub-id pub-id-type="pmid">10512433</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Grover</surname><given-names>M</given-names></name><name><surname>Talwalkar</surname><given-names>S</given-names></name><name><surname>Casbard</surname><given-names>A</given-names></name><name><surname>Boralessa</surname><given-names>H</given-names></name><name><surname>Contreras</surname><given-names>M</given-names></name><name><surname>Boralessa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Silent myocardial ischaemia and haemoglobin concentration: A randomized controlled trial of transfusion strategy in lower limb arthroplasty</article-title><source>Vox Sang</source><year>2006</year><volume>90</volume><issue>2</issue><fpage>105</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1111/j.1423-0410.2006.00730.x</pub-id><pub-id pub-id-type="pmid">16430668</pub-id>
</element-citation><mixed-citation id="mc-CR27" publication-type="journal">Grover M, Talwalkar S, Casbard A, Boralessa H, Contreras M, Boralessa H, et al. Silent myocardial ischaemia and haemoglobin concentration: A randomized controlled trial of transfusion strategy in lower limb arthroplasty. Vox Sang. 2006;90(2):105&#x02013;12.<pub-id pub-id-type="pmid">16430668</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Foss</surname><given-names>NB</given-names></name><name><surname>Kristensen</surname><given-names>MT</given-names></name><name><surname>Jensen</surname><given-names>PS</given-names></name><name><surname>Palm</surname><given-names>H</given-names></name><name><surname>Krasheninnikoff</surname><given-names>M</given-names></name><name><surname>Kehlet</surname><given-names>H</given-names></name></person-group><article-title>The effects of Liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery</article-title><source>Transfusion</source><year>2009</year><volume>49</volume><issue>2</issue><fpage>227</fpage><lpage>34</lpage><pub-id pub-id-type="doi">10.1111/j.1537-2995.2008.01967.x</pub-id><pub-id pub-id-type="pmid">19389209</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Foss NB, Kristensen MT, Jensen PS, Palm H, Krasheninnikoff M, Kehlet H. The effects of Liberal versus restrictive transfusion thresholds on ambulation after hip fracture surgery. Transfusion. 2009;49(2):227&#x02013;34.<pub-id pub-id-type="pmid">19389209</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>So-Osman</surname><given-names>C</given-names></name><name><surname>Nelissen</surname><given-names>R</given-names></name><name><surname>Te Slaa</surname><given-names>R</given-names></name><name><surname>Coene</surname><given-names>L</given-names></name><name><surname>Brand</surname><given-names>R</given-names></name><name><surname>Brand</surname><given-names>A</given-names></name></person-group><article-title>A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells</article-title><source>Vox Sang</source><year>2010</year><volume>98</volume><issue>1</issue><fpage>56</fpage><lpage>64</lpage><pub-id pub-id-type="doi">10.1111/j.1423-0410.2009.01225.x</pub-id><pub-id pub-id-type="pmid">19656349</pub-id>
</element-citation><mixed-citation id="mc-CR29" publication-type="journal">So-Osman C, Nelissen R, Te Slaa R, Coene L, Brand R, Brand A. A randomized comparison of transfusion triggers in elective orthopaedic surgery using leucocyte-depleted red blood cells. Vox Sang. 2010;98(1):56&#x02013;64.<pub-id pub-id-type="pmid">19656349</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>JL</given-names></name><name><surname>Terrin</surname><given-names>ML</given-names></name><name><surname>Noveck</surname><given-names>H</given-names></name><name><surname>Sanders</surname><given-names>DW</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><name><surname>Rhoads</surname><given-names>GG</given-names></name><etal/></person-group><article-title>Liberal or restrictive transfusion in High-Risk patients after hip surgery</article-title><source>N Engl J Med</source><year>2011</year><volume>365</volume><issue>26</issue><fpage>2453</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1012452</pub-id><pub-id pub-id-type="pmid">22168590</pub-id>
</element-citation><mixed-citation id="mc-CR30" publication-type="journal">Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, et al. Liberal or restrictive transfusion in High-Risk patients after hip surgery. N Engl J Med. 2011;365(26):2453&#x02013;62.<pub-id pub-id-type="pmid">22168590</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Gruber-Baldini</surname><given-names>AL</given-names></name><name><surname>Marcantonio</surname><given-names>E</given-names></name><name><surname>Orwig</surname><given-names>D</given-names></name><name><surname>Magaziner</surname><given-names>J</given-names></name><name><surname>Terrin</surname><given-names>M</given-names></name><name><surname>Barr</surname><given-names>E</given-names></name><etal/></person-group><article-title>Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture</article-title><source>J Am Geriatr Soc</source><year>2013</year><volume>61</volume><issue>8</issue><fpage>1286</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1111/jgs.12396</pub-id><pub-id pub-id-type="pmid">23898894</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Gruber-Baldini AL, Marcantonio E, Orwig D, Magaziner J, Terrin M, Barr E, et al. Delirium outcomes in a randomized trial of blood transfusion thresholds in hospitalized older adults with hip fracture. J Am Geriatr Soc. 2013;61(8):1286&#x02013;95.<pub-id pub-id-type="pmid">23898894</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Parker</surname><given-names>MJ</given-names></name></person-group><article-title>Randomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery</article-title><source>Injury</source><year>2013</year><volume>44</volume><issue>12</issue><fpage>1916</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.injury.2013.04.033</pub-id><pub-id pub-id-type="pmid">23756263</pub-id>
</element-citation><mixed-citation id="mc-CR32" publication-type="journal">Parker MJ. Randomised trial of blood transfusion versus a restrictive transfusion policy after hip fracture surgery. Injury. 2013;44(12):1916&#x02013;8.<pub-id pub-id-type="pmid">23756263</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>YX</given-names></name><name><surname>Liu</surname><given-names>FF</given-names></name><name><surname>Jia</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Shen</surname><given-names>JC</given-names></name><name><surname>Zhu</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Comparison of restrictive and Liberal transfusion strategy on postoperative delirium in aged patients following total hip replacement: A preliminary study</article-title><source>Arch Gerontol Geriatr</source><year>2014</year><volume>59</volume><issue>1</issue><fpage>181</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.1016/j.archger.2014.03.009</pub-id><pub-id pub-id-type="pmid">24745810</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Fan YX, Liu FF, Jia M, Yang JJ, Shen JC, Zhu GM, et al. Comparison of restrictive and Liberal transfusion strategy on postoperative delirium in aged patients following total hip replacement: A preliminary study. Arch Gerontol Geriatr. 2014;59(1):181&#x02013;5.<pub-id pub-id-type="pmid">24745810</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Nielsen K, Johansson PI, Dahl B, Wagner M, Frausing B, B&#x000f8;rglum J et al. Perioperative transfusion threshold and ambulation after hip revision surgery - a randomized trial. BMC Anesthesiol. 2014;14(1).</mixed-citation></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name><surname>Carson</surname><given-names>JL</given-names></name><name><surname>Sieber</surname><given-names>F</given-names></name><name><surname>Cook</surname><given-names>DR</given-names></name><name><surname>Hoover</surname><given-names>DR</given-names></name><name><surname>Noveck</surname><given-names>H</given-names></name><name><surname>Chaitman</surname><given-names>BR</given-names></name><etal/></person-group><article-title>Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial</article-title><source>Lancet</source><year>2015</year><volume>385</volume><issue>9974</issue><fpage>1183</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)62286-8</pub-id><pub-id pub-id-type="pmid">25499165</pub-id>
</element-citation><mixed-citation id="mc-CR35" publication-type="journal">Carson JL, Sieber F, Cook DR, Hoover DR, Noveck H, Chaitman BR, et al. Liberal versus restrictive blood transfusion strategy: 3-year survival and cause of death results from the FOCUS randomised controlled trial. Lancet. 2015;385(9974):1183&#x02013;9.<pub-id pub-id-type="pmid">25499165</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name><surname>Gregersen</surname><given-names>M</given-names></name><name><surname>Borris</surname><given-names>LC</given-names></name><name><surname>Damsgaard</surname><given-names>EM</given-names></name></person-group><article-title>Blood transfusion and overall quality of life after hip fracture in frail elderly Patients-The transfusion requirements in frail elderly randomized controlled trial</article-title><source>J Am Med Dir Assoc</source><year>2015</year><volume>16</volume><issue>9</issue><fpage>762</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.jamda.2015.03.022</pub-id><pub-id pub-id-type="pmid">25933728</pub-id>
</element-citation><mixed-citation id="mc-CR36" publication-type="journal">Gregersen M, Borris LC, Damsgaard EM. Blood transfusion and overall quality of life after hip fracture in frail elderly Patients-The transfusion requirements in frail elderly randomized controlled trial. J Am Med Dir Assoc. 2015;16(9):762&#x02013;6.<pub-id pub-id-type="pmid">25933728</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name><surname>Gregersen</surname><given-names>M</given-names></name><name><surname>Borris</surname><given-names>LC</given-names></name><name><surname>Damsgaard</surname><given-names>EM</given-names></name></person-group><article-title>Postoperative blood transfusion strategy in frail, anemic elderly patients with hip fracture: the TRIFE randomized controlled trial</article-title><source>Acta Orthop</source><year>2015</year><volume>86</volume><issue>3</issue><fpage>363</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.3109/17453674.2015.1006980</pub-id><pub-id pub-id-type="pmid">25586270</pub-id>
</element-citation><mixed-citation id="mc-CR37" publication-type="journal">Gregersen M, Borris LC, Damsgaard EM. Postoperative blood transfusion strategy in frail, anemic elderly patients with hip fracture: the TRIFE randomized controlled trial. Acta Orthop. 2015;86(3):363&#x02013;72.<pub-id pub-id-type="pmid">25586270</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name><surname>Gregersen</surname><given-names>M</given-names></name><name><surname>Damsgaard</surname><given-names>EM</given-names></name><name><surname>Borris</surname><given-names>LC</given-names></name></person-group><article-title>Blood transfusion and risk of infection in frail elderly after hip fracture surgery: the TRIFE randomized controlled trial</article-title><source>Eur J Orthop Surg Traumatol</source><year>2015</year><volume>25</volume><issue>6</issue><fpage>1031</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s00590-015-1609-2</pub-id><pub-id pub-id-type="pmid">25690514</pub-id>
</element-citation><mixed-citation id="mc-CR38" publication-type="journal">Gregersen M, Damsgaard EM, Borris LC. Blood transfusion and risk of infection in frail elderly after hip fracture surgery: the TRIFE randomized controlled trial. Eur J Orthop Surg Traumatol. 2015;25(6):1031&#x02013;8.<pub-id pub-id-type="pmid">25690514</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name><surname>Blandfort</surname><given-names>S</given-names></name><name><surname>Gregersen</surname><given-names>M</given-names></name><name><surname>Borris</surname><given-names>LC</given-names></name><name><surname>Damsgaard</surname><given-names>EM</given-names></name></person-group><article-title>Blood transfusion strategy and risk of postoperative delirium in nursing homes residents with hip fracture. A post hoc analysis based on the TRIFE randomized controlled trial</article-title><source>Aging Clin Exp Res</source><year>2017</year><volume>29</volume><issue>3</issue><fpage>459</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1007/s40520-016-0587-5</pub-id><pub-id pub-id-type="pmid">27251666</pub-id>
</element-citation><mixed-citation id="mc-CR39" publication-type="journal">Blandfort S, Gregersen M, Borris LC, Damsgaard EM. Blood transfusion strategy and risk of postoperative delirium in nursing homes residents with hip fracture. A post hoc analysis based on the TRIFE randomized controlled trial. Aging Clin Exp Res. 2017;29(3):459&#x02013;66.<pub-id pub-id-type="pmid">27251666</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><mixed-citation publication-type="other">Zhang J, Chen Z, He Y. Comparison of Liberal versus restrictive transfusion strategies after hip surgery in patients with coronary artery disease: a post hoc analysis of the FOCUS trial. BMC Cardiovasc Disord. 2024;24(1).</mixed-citation></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>AE</given-names></name><name><surname>Refaai</surname><given-names>MA</given-names></name><name><surname>Blumberg</surname><given-names>N</given-names></name></person-group><article-title>Platelet transfusion and thrombosis: more questions than answers</article-title><source>Semin Thromb Hemost</source><year>2016</year><volume>42</volume><issue>2</issue><fpage>118</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">26716501</pub-id>
</element-citation><mixed-citation id="mc-CR41" publication-type="journal">Schmidt AE, Refaai MA, Blumberg N. Platelet transfusion and thrombosis: more questions than answers. Semin Thromb Hemost. 2016;42(2):118&#x02013;24.<pub-id pub-id-type="pmid">26716501</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name><surname>Silliman</surname><given-names>CC</given-names></name><name><surname>Ambruso</surname><given-names>DR</given-names></name><name><surname>Boshkov</surname><given-names>LK</given-names></name></person-group><article-title>Transfusion-related acute lung injury</article-title><source>Blood</source><year>2005</year><volume>105</volume><issue>6</issue><fpage>2266</fpage><lpage>73</lpage><pub-id pub-id-type="doi">10.1182/blood-2004-07-2929</pub-id><pub-id pub-id-type="pmid">15572582</pub-id>
</element-citation><mixed-citation id="mc-CR42" publication-type="journal">Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood. 2005;105(6):2266&#x02013;73.<pub-id pub-id-type="pmid">15572582</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name><surname>Vlaar</surname><given-names>APJ</given-names></name><name><surname>Toy</surname><given-names>P</given-names></name><name><surname>Fung</surname><given-names>M</given-names></name><name><surname>Looney</surname><given-names>MR</given-names></name><name><surname>Juffermans</surname><given-names>NP</given-names></name><name><surname>Bux</surname><given-names>J</given-names></name><etal/></person-group><article-title>A consensus redefinition of transfusion-related acute lung injury</article-title><source>Transfusion</source><year>2019</year><volume>59</volume><issue>7</issue><fpage>2465</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1111/trf.15311</pub-id><pub-id pub-id-type="pmid">30993745</pub-id>
</element-citation><mixed-citation id="mc-CR43" publication-type="journal">Vlaar APJ, Toy P, Fung M, Looney MR, Juffermans NP, Bux J, et al. A consensus redefinition of transfusion-related acute lung injury. Transfusion. 2019;59(7):2465&#x02013;76.<pub-id pub-id-type="pmid">30993745</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>S</given-names></name><name><surname>Wetterslev</surname><given-names>J</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Lichstein</surname><given-names>E</given-names></name><name><surname>Mukherjee</surname><given-names>D</given-names></name></person-group><article-title>Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis</article-title><source>JAMA Intern Med</source><year>2013</year><volume>173</volume><issue>2</issue><fpage>132</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1001/2013.jamainternmed.1001</pub-id><pub-id pub-id-type="pmid">23266500</pub-id>
</element-citation><mixed-citation id="mc-CR44" publication-type="journal">Chatterjee S, Wetterslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and diversity-adjusted study sequential analysis. JAMA Intern Med. 2013;173(2):132&#x02013;9.<pub-id pub-id-type="pmid">23266500</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>SV</given-names></name><name><surname>Eikelboom</surname><given-names>JA</given-names></name><name><surname>Granger</surname><given-names>CB</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Califf</surname><given-names>RM</given-names></name><name><surname>Bassand</surname><given-names>JP</given-names></name></person-group><article-title>Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes</article-title><source>Eur Heart J</source><year>2007</year><volume>28</volume><issue>10</issue><fpage>1193</fpage><lpage>204</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehm019</pub-id><pub-id pub-id-type="pmid">17456480</pub-id>
</element-citation><mixed-citation id="mc-CR45" publication-type="journal">Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand JP. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(10):1193&#x02013;204.<pub-id pub-id-type="pmid">17456480</pub-id>
</mixed-citation></citation-alternatives></ref></ref-list></back></article>